Tislelizumab

Monoclonal antibody

Approvedregulatory verdict

Evidence outlook

Approved: Esophageal Squamous Cell Carcinoma, Gastric Cancer

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

Also in development:Non-Small Cell Lung Cancer · Phase 3Nasopharyngeal Carcinoma · Phase 3Small Cell Lung Cancer · Phase 3

Also approved (5)
US
  • First-line treatment of adults with HER2-positive (IHC 3+ or IHC 2+/ISH+) unresectable locally advanced or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma, in combination with zanidatamab-hrii and fluoropyrimidine- and platinum-containing chemotherapy
Product first approved 2024Outside this platform's coverageFDA label
CA
  • TEVIMBRA (tislelizumab for injection) • in combination with gemcitabine and cisplatin is indicated for the first-line treatment of adult patients with recurrent or metastatic nasopharyngeal carcinoma (NPC). • as monotherapy, is indicated for the treatment of adult patients with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) after one prior systemic chemotherapy that did not include a PD-(L)1 inhibitor.
Product first approved 2025Health Canada
JP
  • Treatment of unresectable advanced or recurrent esophageal cancer
Product first approved 2025Outside this platform's coveragePMDA
EU
  • Oesophageal squamous cell carcinoma (EPAR also lists NSCLC, SCLC, gastric/GEJ adenocarcinoma, nasopharyngeal carcinoma)
Product first approved 2023EMA
CN
  • Classical Hodgkin lymphoma after at least two prior therapies (first China approval)
Product first approved 2019biospace.com

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (57)
Esophageal Squamous Cell Carcinoma
NCT06914011 · Asan Medical Center
2026-12-31 – 2034-05-30 · Esophageal Cancer
What this study did
Gastric Cancer
NCT07068516 · Xiangdong Cheng
2025-07-20 – 2030-06-30 · Gastric Cancer Stage
What this study did
NCT06939439 · The First Affiliated Hospital with Nanjing Medical University
2024-12-01 – 2029-12-31 · Gastric Cancer Stage III
What this study did
Nasopharyngeal Carcinoma
NCT07373990 · Sun Yat-sen University
2026-01-15 – 2030-12-31 · Nasopharyngeal Cancinoma (NPC), Nasopharyngeal Cancer
What this study did
NCT06383780 · XIANG YANQUN
2024-05-15 – 2029-05-15 · Nasopharyngeal Carcinoma
What this study did
NCT05211232 · Sun Yat-sen University
2022-06-10 – 2028-06-02 · Nasopharyngeal Carcinoma
What this study did
NCT06177301 · Fudan University
2023-12-01 – 2027-12 · Nasopharyngeal Carcinoma
What this study did
Non-Small Cell Lung Cancer
NCT07715396 · AIO-Studien-gGmbH
2026-10-30 – 2031-10-30 · Non-small Cell Lung Cancer Metastatic
What this study did
NCT06704620 · Tianjin Medical University Cancer Institute and Hospital
2024-12 – 2027-11 · Advanced and Metastatic NSCLC
What this study did
NCT04379635 · BeiGene
2020-05-29 – 2027-03-31 · Non Small Cell Lung Cancer
What this study did
NCT04921358 · BeiGene
2021-07-27 – 2023-12-20 · Non-Small Cell Lung Cancer (NSCLC)
What this study did
NCT03594747 · BeiGene
2018-07-30 – 2023-04-28 · Non-Small Cell Lung Cancer
What this study did
NCT03663205 · BeiGene
2018-07-23 – 2023-04-26 · Non-Small Cell Lung Cancer
What this study did
Small Cell Lung Cancer
NCT07502300 · Sichuan Baili Pharmaceutical Co., Ltd.
2026-06-15 – 2029-12 · Extensive-stage Small-cell Lung Cancer
What this study did
Other / comorbidity
NCT06441110 · Fujian Medical University Union Hospital
2023-06-01 – 2035-06-01 · Urinary Bladder Neoplasms, BCG Vaccine, Immunotherapy, Active, Multicenter Study, Treatment Outcome, Neoplasm Recurrence, Local
What this study did
NCT07900061 · Sir Run Run Shaw Hospital
2026-10-25 – 2034-12 · Rectal Cancer
What this study did
NCT07763171 · Gruppo Oncologico del Nord-Ovest
2026-09-01 – 2031-09 · Gastroesophageal Adenocarcinoma
What this study did
NCT06957938 · Fudan University
2025-04-28 – 2031-05-01 · Laryngeal Carcinoma, Hypopharyngeal Carcinoma
What this study did
NCT07475026 · Tianjin Medical University Cancer Institute and Hospital
2026-06-09 – 2030-12-31 · HCC - Hepatocellular Carcinoma
What this study did
NCT07132463 · Fudan University
2025-08-12 – 2030-12 · Rectal Cancer
What this study did
NCT06520683 · Sun Yat-sen University
2024-11-01 – 2030-11-01 · Colorectal Cancer, Microsatellite Instability High
What this study did
NCT05582265 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
2022-10-28 – 2030-10 · Head and Neck Squamous Cell Carcinomas
What this study did
NCT07132008 · First Affiliated Hospital of Guangxi Medical University
2025-10-01 – 2030-09-30 · Colonic Neoplasms, Neoadjuvant Therapy, Immune Checkpoint Inhibitors
What this study did
NCT07691515 · Zhejiang Cancer Hospital
2026-09 – 2030-07 · Intrahepatic Cholangiocarcinoma (Icc)
What this study did
NCT07385703 · Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
2026-04-15 – 2030-05 · Adenocarcinoma
What this study did
NCT06332274 · Gustave Roussy, Cancer Campus, Grand Paris
2025-04-16 – 2030-04 · Cancer, Lung Cancer, Colo-rectal Cancer, Pancreas Cancer, Soft Tissue Sarcoma
What this study did
NCT06258811 · Lai-ping Zhong
2024-02-20 – 2029-12-30 · Oral Squamous Cell Carcinoma, Locally Advanced Head and Neck Carcinoma
What this study did
NCT06465446 · ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
2024-06 – 2029-07 · Classic Hodgkin Lymphoma
What this study did
NCT07043400 · BeOne Medicines
2025-08-27 – 2028-04-22 · Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
What this study did
NCT05823311 · Second Affiliated Hospital, Zhejiang University, School of Medicine
2023-09-01 – 2027-12-31 · Advanced Cholangiocarcinoma
What this study did
NCT03967977 · BeiGene
2019-05-29 – 2027-10-21 · Urothelial Carcinoma
What this study did
NCT05152147 · Jazz Pharmaceuticals
2021-12-02 – 2027-09-30 · Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma
What this study did
NCT04170283 · BeOne Medicines
2020-01-16 – 2026-12-31 · B-cell Malignancies
What this study did
NCT06017583 · Yong Zhang,MD
2023-09-01 – 2026-08-31 · Rectal Neoplasms
What this study did
NCT04164199 · BeOne Medicines
2019-12-19 – 2026-05-23 · Advanced Malignancies
What this study did
NCT05207709 · SOLTI Breast Cancer Research Group
2022-03-28 – 2026-03-26 · Metastatic Breast Cancer
What this study did
Phase 2/3 (8)
Esophageal Squamous Cell Carcinoma
NCT04973306 · Shanghai Zhongshan Hospital
2022-03-02 – 2027-07 · Esophageal Squamous Cell Carcinoma Stage II, Esophageal Squamous Cell Carcinoma Stage III
What this study did
Gastric Cancer
NCT05325528 · Zhejiang University
2022-04-10 – 2025-12-31 · Liver Metastases
What this study did
Non-Small Cell Lung Cancer
NCT07131319 · Second Affiliated Hospital of Nanchang University
2025-04-21 – 2028-12-31 · Non-Small Cell Lung Cancer
What this study did
Other / comorbidity
NCT06563245 · Children's Cancer Group, China
2024-09-25 – 2039-11-15 · Classical Hodgkin Lymphoma, Child, Adolescent, Young Adult, Metabolic Response, Survival, Treatment, Brentuximab Vedotin, PET Scan
What this study did
NCT06443671 · Peking University Cancer Hospital & Institute
2024-06-01 – 2028-06-01 · Rectal Cancer
What this study did
NCT06312982 · Beijing Friendship Hospital
2024-03-16 – 2026-12-01 · Locally Advanced Rectal Carcinoma
What this study did
Phase 2 (396)
Esophageal Squamous Cell Carcinoma
NCT07721103 · Tianjin Medical University Cancer Institute and Hospital
2026-07-14 – 2031-12-31 · Esophageal Squamous Cell Carcinoma (ESCC)
What this study did
NCT07554521 · BeOne Medicines
2026-04-30 – 2031-12-31 · Advanced Unresectable Gastric Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Advanced Gastroesophageal Adenocarcinoma
What this study did
NCT07205731 · University Hospital, Clermont-Ferrand
2025-10-07 – 2030-10 · Esophageal Squamous Cell Carcinoma (ESCC)
What this study did
NCT07046221 · Fujian Cancer Hospital
2025-08-01 – 2030-08-01 · Esophagus Cancer
What this study did
NCT07531979 · Tianjin Medical University Cancer Institute and Hospital
2026-04-01 – 2029-12-31 · ESCC, Tislelizumab, Chemotherapy, Becotatug Vedotin, EGFR ADC, PD-1 Inhibitor
What this study did
NCT07686926 · Tianjin Medical University Cancer Institute and Hospital
2026-08-01 – 2029-12-31 · Esophageal Squamous Cell Carcinoma
What this study did
NCT07700667 · Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
2026-08-13 – 2029-12-31 · Esophageal Squamous Cell Carcinoma
What this study did
NCT07678580 · Tang-Du Hospital
2026-07-10 – 2029-06-30 · Esophageal Squamous Cell Carcinoma (ESCC)
What this study did
NCT07039162 · Ming-Yu Lien
2025-09-26 – 2028-12-31 · Esophageal Squamous Cell Carcinoma (ESCC), Locally Advanced Unresectable Esophageal Cancer
What this study did
NCT07811752 · Shanghai Chest Hospital
2026-07-30 – 2028-12-31 · Esophageal Squamous Cell Carcinoma
What this study did
NCT07128693 · The First Affiliated Hospital of Zhengzhou University
2025-09 – 2028-12 · Esophageal Squamous Cell Carcinoma
What this study did
NCT06764355 · National Taiwan University Hospital
2025-07-23 – 2028-12 · ESCC, Total Neoadjuvant Treatment, Pathological Complete Response
What this study did
NCT06354140 · Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
2024-05-07 – 2028-05-30 · Esophageal Squamous Cell Carcinoma
What this study did
NCT07733180 · BeOne Medicines
2026-09-14 – 2028-02-28 · Advanced Esophageal Squamous Cell Carcinoma, Metastatic Esophageal Squamous Cell Carcinoma
What this study did
NCT05515315 · Fuzhou General Hospital
2022-05-31 – 2027-05-31 · Immunotherapy Esophagus Cancer
What this study did
NCT06646588 · Hebei Medical University Fourth Hospital
2024-04-01 – 2027-04-30 · Esophageal Neoplasms
What this study did
NCT06692270 · Fujian Cancer Hospital
2025-05-15 – 2027-01-10 · Esophagus Cancer
What this study did
NCT06056336 · Guo Xufeng
2023-09-07 – 2026-12-31 · Esophageal Squamous Cell Carcinoma, Neoadjuvant Chemoimmunotherapy, Adjuvant Therapy
What this study did
NCT06446726 · Sichuan University
2024-06-30 – 2026-12-30 · Esophageal Squamous Cell Carcinoma
What this study did
NCT05520619 · Sun Yat-sen University
2022-09-15 – 2026-07-31 · Esophageal Squamous Cell Carcinoma, Locally Advanced Esophageal Squamous Cell Carcinoma
What this study did
NCT06010303 · BeiGene
2023-11-08 – 2026-05-07 · Esophageal Cancer, Esophageal Squamous Cell Carcinoma, Esophageal Squamous Cell Carcinoma by AJCC V8 Stage
What this study did
NCT05596890 · Guangdong Provincial People's Hospital
2022-11-30 – 2025-09-30 · Esophageal Squamous Cell Carcinoma, Patient-reported Outcomes, Immunotherapy
What this study did
NCT05880082 · Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
2023-01-13 – 2025-08-18 · Esophageal Squamous Cell Carcinoma
What this study did
NCT05449483 · Tianjin Medical University Cancer Institute and Hospital
2022-05-11 – 2025-06-30 · Esophageal Squamous Cell Carcinoma by AJCC V8 Stage, Unresectable
What this study did
NCT05547828 · The First Affiliated Hospital of Xinxiang Medical College
2022-12-20 – 2024-12-20 · ESCC
What this study did
NCT04974047 · BeiGene
2021-08-17 – 2024-10-25 · Resectable Esophageal Squamous Cell Carcinoma
What this study did
NCT05323890 · Shandong Cancer Hospital and Institute
2022-04-20 – 2024-10-20 · Advanced Esophageal Squamous Cell Cancer
What this study did
NCT05461794 · BeiGene
2022-10-03 – 2024-02-26 · Esophageal Squamous Cell Carcinoma
What this study did
NCT05469061 · The First Affiliated Hospital with Nanjing Medical University
2022-01-01 – 2022-11-01 · Esophageal Squamous Cell Carcinoma, Locally Advanced Carcinoma
What this study did
NCT03469557 · BeiGene
2017-07-18 – 2020-08-19 · Esophageal Squamous Cell Carcinoma, Gastric Carcinoma, Gastroesophageal Junction Carcinoma
What this study did
Gastric Cancer
NCT07655661 · Ming Liu
2026-07-01 – 2029-07-01 · Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
What this study did
NCT06238167 · First Affiliated Hospital of Wenzhou Medical University
2024-04-01 – 2028-12-31 · Gastric Cancer
What this study did
NCT07685704 · Zhifeng Zhao, PhD
2026-07 – 2028-12 · Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, HER2-positive Gastric Cancer
What this study did
NCT06560528 · Tianjin Medical University Cancer Institute and Hospital
2024-09-01 – 2028-09-01 · Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
What this study did
NCT06374901 · Xiangdong Cheng
2024-04-25 – 2028-03-31 · Gastric Cancer
What this study did
NCT06764251 · Liaoning Cancer Hospital & Institute
2024-12-30 – 2028-03-31 · Gastric/Gastroesophageal Junction Adenocarcinoma
What this study did
NCT07304258 · Hebei Medical University
2025-12-12 – 2027-12-31 · Gastric Cancer Peritoneal Metastases
What this study did
NCT06451211 · Sun Yat-sen University
2023-05-17 – 2027-11 · Stomach Neoplasms, Gastric Cancer, Linitis Plastica of Stomach
What this study did
NCT05536102 · Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
2022-09-05 – 2027-09-30 · Gastric Cancer
What this study did
NCT05687357 · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
2023-03-15 – 2027-08-31 · Gastric Cancer, Gastroesophageal-junction Cancer
What this study did
NCT06157996 · Nanfang Hospital, Southern Medical University
2024-06-01 – 2026-08 · Gastric Cancer
What this study did
NCT05515796 · Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
2022-09-01 – 2026-03-25 · Immunotherapy, Gastric Cancer, Rectal Cancer, Chemotherapy Effect, Radiotherapy
What this study did
NCT04799548 · Shanghai Zhongshan Hospital
2021-12-30 – 2026-01 · Advanced Gastric Cancer
What this study did
NCT05586061 · Qilu Hospital of Shandong University
2023-02-10 – 2025-12-31 · HER2-positive Gastric Cancer
What this study did
NCT05893056 · Fudan University
2023-06-16 – 2025-12-30 · Gastric Cancer Metastatic to Liver
What this study did
NCT05751265 · Fujian Cancer Hospital
2023-07-01 – 2025-06-01 · Gastric Cancer
What this study did
NCT06197438 · Fujian Cancer Hospital
2024-01-01 – 2025-04-01 · Gastric Cancer
What this study did
NCT04363801 · Leap Therapeutics, Inc.
2020-07-29 – 2025-03-31 · Gastric Cancer, Gastric Adenocarcinoma, GastroEsophageal Cancer
What this study did
NCT05223088 · Fujian Cancer Hospital
2021-10-31 – 2024-04-30 · Immunotherapy, Gastrict Cancer
What this study did
Phase 1/2 (62)
Esophageal Squamous Cell Carcinoma
NCT06303583 · Qiu Guoqin
2022-06-01 – 2026-12-31 · Esophageal Squamous Cell Carcinoma
What this study did
NCT05394415 · Jiangsu Cancer Institute & Hospital
2022-05-01 – 2025-04-30 · Esophageal Squamous Cell Carcinoma, Tislelizumab, Chemoradiation
What this study did
Gastric Cancer
NCT06871527 · Sixth Affiliated Hospital, Sun Yat-sen University
2025-03-01 – 2028-12-31 · Gastric (Stomach) Cancer, Gastric Adenocarcinoma, Fruquintinib, PD-1 Inhibitor, Tislelizumab, GEJ Adenocarcinoma
What this study did
NCT06266871 · West China Hospital
2024-03-10 – 2026-07-30 · Gastric Cancer
What this study did
NCT05632939 · AskGene Pharma, Inc.
2023-02-21 – 2026-02-10 · Gastric Cancer, Gastroesophageal Cancer (GC)
What this study did
NCT05319639 · Fujian Cancer Hospital
2023-02-16 – 2025-12-31 · Gastric Cancer Stage IV
What this study did
NCT05982834 · Fudan University
2023-05-09 – 2025-12 · HER2-positive Gastric Cancer, Immunotherapy
What this study did
NCT04276493 · BeiGene
2020-03-23 – 2024-10-31 · Breast Cancer, Gastric Cancer, Gastroesophageal Junction Cancer
What this study did
Non-Small Cell Lung Cancer
NCT07468071 · Novartis Pharmaceuticals
2026-06-08 – 2029-09-11 · Locally Advanced or Metastatic KRAS G12C-mutated Non-small Cell Lung Cancer, Advanced Solid Tumors Harboring the KRAS G12C Mutation
What this study did
NCT06456138 · Shanghai Chest Hospital
2024-07-01 – 2028-12-31 · KRAS Mutation-Related Tumors, Advanced Lung Cancer, Refractory Tumor
What this study did
NCT07846358 · Genfleet Therapeutics (Shanghai) Inc.
2026-11 – 2028-12 · RAS Mutation, Non-small Cell Lung Cancer (NSCLC)
What this study did
NCT06427941 · BeOne Medicines
2024-07-23 – 2028-10-31 · Metastatic Hepatocellular Carcinoma, Local Advanced Hepatocellular Carcinoma, Alpha-fetoprotein (AFP)-Producing Gastric Cancer, Extragonadal Yolk Sac Tumors, Glypican-3 (GPC3)-Positive Squamous Non-small Cell Lung Cancer
What this study did
NCT05431270 · Phanes Therapeutics
2022-08-11 – 2028-08 · Non Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma
What this study did
NCT05651022 · Indaptus Therapeutics, Inc
2023-02-28 – 2027-09-30 · Solid Tumor, Adult, HCC - Hepatocellular Carcinoma, CRC (Colorectal Cancer), Pancreatic Adenocarcinoma, NSCLC Non-small Cell Lung Cancer, Squamous Cell Cancer of the Head and Neck, UC (Urothelial Cancer), MSI-H Cancer
What this study did
NCT04699188 · Novartis Pharmaceuticals
2021-02-24 – 2027-01-25 · KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small-Cell Lung, Carcinoma, Colorectal, Cancer of Lung, Cancer of the Lung, Lung Cancer, Neoplasms, Lung, Neoplasms, Pulmonary, Pulmonary Cancer, Pulmonary Neoplasms
What this study did
NCT06136910 · Fujian Cancer Hospital
2023-05-09 – 2025-12-31 · Untreated Advanced Non-small Cell Lung Cancer
What this study did
NCT03744468 · BeiGene
2018-11-13 – 2025-02-06 · Locally Advanced or Metastatic Solid Tumors for Phase 1, Dose Escalation and Phase 2 Safety Lead-in, HNSCC for Phase 2 Dose Expansion, NSCLC for Phase 2 Dose Expansion
What this study did
Small Cell Lung Cancer
NCT06030258 · InxMed (Shanghai) Co., Ltd.
2023-10-30 – 2027-01-31 · Small Cell Lung Cancer Extensive Stage
What this study did
NCT04579757 · Hutchmed
2021-03-05 – 2024-08-27 · Metastatic Solid Tumor, Colorectal Cancer, Neuroendocrine Tumors, Small Cell Lung Cancer, Gastric Cancer, Soft Tissue Sarcoma, Anaplastic Thyroid Cancer
What this study did
Other / comorbidity
NCT07847905 · LaNova Medicines Limited
2026-10-20 – 2031-08-19 · Advanced Solid Tumor Cancer
What this study did
NCT07694765 · LaNova Medicines Limited
2026-07-15 – 2030-12-31 · Malignant Tumors
What this study did
NCT07502768 · Rong Tao
2026-04-30 – 2028-12-30 · Extranodal NK/T-cell Lymphoma, NK/T-cell Lymphoma, Relapsed or Refractory NK/T-Cell Lymphoma
What this study did
NCT07681297 · National University Hospital, Singapore
2026-08 – 2028-08 · Advanced Solid Tumor Cancer, Triple-Negative Breast Cancer (TNBC), CNS Disease, Breast Cancer
What this study did
NCT05675813 · Ruijin Hospital
2023-02-13 – 2028-07-15 · Peripheral T Cell Lymphoma
What this study did
NCT07244705 · Anbogen Therapeutics, Inc.
2025-11 – 2028-07 · Colorectal Cancer (Diagnosis), Colorectal Cancer Metastatic, Colorectal Cancer (CRC), Immunotherapy
What this study did
NCT05886439 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences
2023-05-11 – 2028-05-30 · Lung Cancer
What this study did
NCT07561060 · Fudan University
2024-01-01 – 2028-03 · Rectal Cancer
What this study did
NCT05978102 · The Fourth Affiliated Hospital of Zhejiang University School of Medicine
2023-08-23 – 2027-06 · Advanced Solid Tumor
What this study did
NCT07010120 · West China Hospital
2025-06-10 – 2027-05-31 · HNSCC, Lysogenic HSV Virus, Neoadjuvant Therapy, Immunotherapy, Targeted Therapy
What this study did
NCT07025850 · Fudan University
2025-08-01 – 2027-05-01 · Colorectal Carcinoma
What this study did
NCT05982522 · InxMed (Shanghai) Co., Ltd.
2025-08-13 – 2026-12-31 · Solid Tumor
What this study did
NCT05609370 · BeiGene
2023-01-29 – 2026-12-31 · Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer
What this study did
NCT06499350 · FindCure Biosciences (ZhongShan) Co., Ltd.
2024-11-13 – 2026-12-30 · Advanced Malignant Solid Tumors
What this study did
NCT05661955 · BeiGene
2023-01-09 – 2026-10 · Urothelial Carcinoma, Renal Cell Carcinoma, Melanoma, Non-mucosal Melanoma
What this study did
NCT06825494 · Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
2025-04-08 – 2026-09 · Advanced Solid Tumor
What this study did
NCT06364956 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
2024-05-15 – 2026-06 · Bladder Cancer
What this study did
NCT05516914 · Nanjing Leads Biolabs Co.,Ltd
2022-09-01 – 2026-01-30 · Malignant Tumors
What this study did
NCT05906524 · Shanghai Kanda Biotechnology Co., Ltd.
2024-04-15 – 2025-12-31 · Advanced HCC, Other Solid Tumors
What this study did
NCT06394791 · The First Affiliated Hospital with Nanjing Medical University
2024-05-01 – 2025-12-31 · Left-sided Colorectal Cancer Complicating Acute Obstruction
What this study did
NCT04425070 · Antengene Corporation
2020-08-18 – 2025-12-30 · Peripheral T-cell Lymphoma, NK/T-cell Lymphoma
What this study did
NCT05464433 · Sun Yat-sen University
2022-06-23 – 2025-11-30 · Extranodal Natural Killer T Cell Lymphoma
What this study did
NCT06471673 · BriaCell Therapeutics Corporation
2024-05-29 – 2025-10-30 · Breast Cancer, Breast Tumor, Cancer of Breast, Cancer of the Breast, Malignant Tumor of Breast, Tumors, Breast
What this study did
NCT05746728 · Huihua Xiong
2023-04 – 2025-08 · Metastatic Triple-negative Breast Cancer
What this study did
NCT06586099 · Institute of Hematology & Blood Diseases Hospital, China
2024-10-05 – 2025-06-01 · Refractory AML, Relapsed Adult AML
What this study did
NCT05505877 · Shanghai Gopherwood Biotech Co., Ltd.
2022-09-10 – 2024-12-31 · Advanced Solid Tumor
What this study did
NCT04666688 · PureTech
2020-12-11 – 2024-12-12 · Metastatic Cancer, Solid Tumor, Head and Neck Cancer
What this study did
NCT05833984 · ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
2022-05-17 – 2024-11-20 · Solid Tumor, Classic Hodgkin Lymphoma
What this study did
NCT05842317 · Peking Union Medical College Hospital
2022-09-01 – 2024-11-15 · Hepatocellular Carcinoma
What this study did
NCT05267054 · BeiGene
2022-04-25 – 2024-08-30 · Relapsed Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-cell Lymphoma
What this study did
NCT04282018 · BeiGene
2020-04-29 – 2024-08-28 · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma, Mantle Cell Lymphoma, Diffuse Large B Cell Lymphoma, Advanced Solid Tumor
What this study did
Phase 1 (69)
Esophageal Squamous Cell Carcinoma
NCT05984342 · Affiliated Cancer Hospital of Shantou University Medical College
2023-08-02 – 2029-06-30 · Esophageal Squamous Cell Carcinoma
What this study did
NCT07317609 · Shanghai Zhongshan Hospital
2025-07-15 – 2027-09-30 · Esophageal Squamous Cell Carcinoma (ESCC)
What this study did
NCT06690476 · Peking University
2024-10-10 – 2026-10 · Esophageal Squamous Cell Carcinoma
What this study did
Gastric Cancer
NCT05768932 · SillaJen, Inc.
2022-12-14 – 2026-12-24 · Advanced Solid Tumor, TNBC - Triple-Negative Breast Cancer, Gastric Cancer, Leukemia Acute Myeloid Leukemia (AML)
What this study did
Non-Small Cell Lung Cancer
NCT06868732 · Jiangsu Alphamab Biopharmaceuticals Co., Ltd
2025-04-02 – 2028-12-30 · Advanced Non-small Cell Lung Cancer
What this study did
NCT07842887 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences
2026-10-01 – 2028-10-10 · EGFR-TKI-resistant Non-Small Cell Lung Cancer
What this study did
NCT06969612 · Peking University Cancer Hospital & Institute
2025-05-15 – 2028-05 · NSCLC (Advanced Non-small Cell Lung Cancer)
What this study did
NCT05238883 · HiFiBiO Therapeutics
2022-03-10 – 2026-12 · Gastric Cancer, Renal Cell Carcinoma, Melanoma, Sarcoma, Testicular Germ Cell Tumor, Cervical Cancer, Mesothelioma, Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma
What this study did
NCT05789069 · HiFiBiO Therapeutics
2023-05-09 – 2026-12 · Renal Cell Carcinoma, Melanoma, Non Small Cell Lung Cancer, Gastric Cancer, Colorectal Cancer
What this study did
NCT06585488 · BeOne Medicines
2024-12-13 – 2026-04-23 · Metastatic Solid Tumors, Advanced Non-squamous Non-small-cell Lung Cancer, Advanced Colorectal Cancer, Advanced Pancreatic Ductal Adenocarcinoma, Advanced Gastric Cancer, Advanced Gastroesophageal Junction Cancer, Advanced Esophageal Adenocarcinoma
What this study did
NCT04215978 · BeiGene
2020-01-30 – 2025-01-24 · Advanced Solid Tumor, Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma (HNSCC), Nasopharyngeal Carcinoma (NPC)
What this study did
NCT05273814 · Tianjin Medical University Cancer Institute and Hospital
2022-08-01 – 2024-02-01 · Non-Small Cell Lung Cancer
What this study did
NCT04261439 · Novartis Pharmaceuticals
2020-02-27 – 2023-12-27 · In Escalation: All Patients With Solid Tumors and Lymphoma, In Expansion: Melanoma, Non-small Cell Lung Cancer
What this study did
Small Cell Lung Cancer
Other / comorbidity
NCT07341360 · Oslo University Hospital
2025-10-13 – 2034-12-31 · Pseudomyxoma Peritonei
What this study did
NCT07353294 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
2026-01-01 – 2029-06-30 · Bladder Urothelial Carcinoma, Lymph Node Metastasis
What this study did
NCT07414836 · BeOne Medicines
2026-04-13 – 2029-04-30 · Advanced Solid Tumor
What this study did
NCT07377045 · Oncomatryx Biopharma S.L.
2025-10-28 – 2029-03 · Pancreatic Adenocarcinoma Metastatic
What this study did
NCT05981703 · BeOne Medicines
2023-09-21 – 2029-02-28 · Advanced Solid Tumor, Solid Tumor
What this study did
NCT07077369 · West China Hospital
2025-08-01 – 2028-12-31 · Hepatocellular Carcinoma (HCC)
What this study did
NCT06541639 · Peking University
2025-03-04 – 2028-12 · Advanced or Recurrent Solid Tumors
What this study did
NCT06349837 · Sichuan University
2024-04-18 – 2028-11-30 · Solid Tumor
What this study did
NCT07746141 · BeOne Medicines
2026-09-02 – 2028-09-30 · RAS Mutation, Advanced Solid Tumor, Metastatic Solid Tumor
What this study did
NCT06596473 · BeOne Medicines
2024-10-03 – 2028-07-23 · Advanced Solid Tumors
What this study did
NCT07671339 · Memorial Sloan Kettering Cancer Center
2026-06-22 – 2028-06 · Pancreatic Cancer
What this study did
NCT07389187 · Shanghai Changzheng Hospital
2027-06 – 2028-06 · mCRPC
What this study did
NCT06233942 · BeOne Medicines
2024-04-12 – 2028-05-15 · Advanced Solid Tumor
What this study did
NCT07565740 · West China Hospital
2026-05-15 – 2028-05-10 · HPV-positive Oropharyngeal Squamous Cell Carcinoma
What this study did
NCT04387084 · University of Southern California
2020-08-12 – 2028-03-31 · Advanced Malignant Skin Neoplasm, Metastatic Malignant Skin Neoplasm
What this study did
NCT05526924 · University of Chicago
2023-03-07 – 2028-01-01 · Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Head and Neck Carcinoma, Head and Neck Cancer Stage IV, Head and Neck Cancers - Throat
What this study did
NCT07453875 · Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
2026-05 – 2027-12-30 · Peritoneal Metastasis of Gastric and Colorectal Cancer, LDRT
What this study did
NCT05547321 · Oncomatryx Biopharma S.L.
2022-10-20 – 2027-12 · Advanced Solid Tumor
What this study did
NCT06848465 · Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
2025-02-28 – 2027-11-30 · Colorectal Cancer, Liver Metastasis, LDRT
What this study did
NCT07059299 · Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
2025-12-12 – 2027-08 · Esophagogastric Junction Adenocarcinoma, Gastric Adenocarcinoma, Esophageal Adenocarcinoma, Resectable Esophagogastric Adenocarcinoma, Neoadjuvant Therapy
What this study did
NCT07348107 · Daniel Breadner
2026-02-15 – 2027-03 · Advanced Pancreatic Ductal Adenocarcinoma
What this study did
NCT07119996 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
2025-08-01 – 2027-02-01 · Bladder (Urothelial, Transitional Cell) Cancer
What this study did
NCT06741982 · West China Hospital
2024-12-15 – 2026-12-15 · HNSCC, Lysogenic HSV Virus, Neoadjuvant Therapy, Immunotherapy, Targeted Therapy
What this study did
NCT05659628 · Ningbo No. 1 Hospital
2022-12 – 2026-12 · Diffuse Large B-cell Lymphoma
What this study did
NCT06463444 · Chen Xiaoping
2024-06-01 – 2026-06-30 · HCC, Precision Therapy
What this study did
NCT05167071 · Harbour BioMed (Guangzhou) Co. Ltd.
2021-12-28 – 2026-06-30 · Solid Tumors, Neuroendocrine Tumors, CRC
What this study did
NCT06422520 · BeOne Medicines
2024-07-08 – 2026-05-15 · Advanced Solid Tumor
What this study did
NCT04649385 · BeiGene
2021-03-04 – 2026-05-15 · Advanced Solid Tumor
What this study did
NCT06487858 · BeOne Medicines
2024-07-16 – 2026-04-09 · Solid Tumor
What this study did
NCT05935098 · BeiGene
2023-08-21 – 2026-01-27 · Advanced Solid Tumor, Metastatic Solid Tumor, Solid Tumor
What this study did
NCT06916494 · First Affiliated Hospital of Chongqing Medical University
2025-05-01 – 2026-01-20 · Muscle Invasive Bladder Cancer
What this study did
NCT06540066 · BeiGene
2024-09-11 – 2026-01-09 · Advanced Cancer, Advanced Solid Tumor, Metastatic Cancer, Metastatic Solid Tumor
What this study did
NCT05675462 · Fudan University
2023-03-01 – 2025-12-30 · Hepatocellular Carcinoma
What this study did
Phase 4 (12)
Esophageal Squamous Cell Carcinoma
NCT05603065 · First Affiliated Hospital Xi'an Jiaotong University
2022-10-10 – 2024-10 · Esophageal Squamous Cell Carcinoma
What this study did
Non-Small Cell Lung Cancer
NCT07744698 · Anhui Provincial Cancer Hospital
2026-07-24 – 2029-06 · Squamous Non-Small Cell Lung Cancer sqNSCLC, Extensive-stage Small Cell Lung Cancer (ES-SCLC)
What this study did
NCT07320105 · Fujian Cancer Hospital
2026-01-15 – 2029-01-31 · Non-Small Cell Lung Cancer
What this study did
NCT06356675 · The First Affiliated Hospital, Guangzhou University of Traditional Chinese Medicine
2024-07-01 – 2028-07-01 · Advanced NSCLC
What this study did
NCT06357598 · The Affiliated Hospital of Qingdao University
2024-01-18 – 2025-12-31 · Non-small-cell Lung Cancer (NSCLC)
What this study did
Small Cell Lung Cancer
NCT07485920 · The Affiliated Hospital of Qingdao University
2026-05-01 – 2030-01-31 · Limited-stage Small Cell Lung Cancer (LS-SCLC)
What this study did
Other / comorbidity
NCT05861635 · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
2023-02-01 – 2026-02-01 · Breast Cancer, Neoadjuvant Therapy
What this study did
NCT06761911 · Xiuhua Sun
2024-12-31 – 2026-01-31 · Hodgkin Lymphoma (Category)
What this study did
NCT06003673 · First Affiliated Hospital of Fujian Medical University
2023-07-01 – 2025-07-01 · Hepatocellular Carcinoma Resectable
What this study did
NCT05580354 · Ruijin Hospital
2022-10-09 – 2025-05-31 · Non-muscle-invasive Bladder Cancer
What this study did
Early phase / not applicable (17)
Nasopharyngeal Carcinoma
NCT07248696 · Chongqing University Cancer Hospital
2025-10-04 – 2029-06-30 · Nasopharyngeal Cancinoma (NPC)
What this study did
Non-Small Cell Lung Cancer
NCT06056115 · Hebei Medical University Fourth Hospital
2023-05-01 – 2026-12-12 · Lung Adenocarcinoma
What this study did
NCT05527808 · Jun Liu
2022-08-01 – 2025-12-30 · Lung Adenocarcinoma
What this study did
NCT06607926 · Xuanwu Hospital, Beijing
2024-10-15 – 2025-12-30 · Resectable Non-Small-Cell Lung Cancer
What this study did
Small Cell Lung Cancer
NCT05027100 · Haibo Zhang
2021-09-30 – 2023-06 · Small Cell Lung Cancer (SCLC)
What this study did
Other / comorbidity
NCT07068542 · Zhejiang Provincial People's Hospital
2025-07-01 – 2028-12-31 · Advanced Thyroid Carcinoma, Radioiodine-refractory Differentiated Thyroid Cancer, Poorly Differentiated Thyroid Carcinoma
What this study did
NCT07480382 · Hong Wu
2026-04-01 – 2028-06-30 · Initially Unresectable Hepatocellular Carcinoma
What this study did
NCT07243691 · Sir Run Run Shaw Hospital
2025-12-01 – 2027-12-15 · Hepatocellular Carcinoma
What this study did
NCT07535840 · Tongji Hospital
2026-05 – 2027-06 · HCC - Hepatocellular Carcinoma, TP53 Gene Mutation, Unresectable, Resistant Cancer
What this study did
NCT07396090 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences
2026-01-20 – 2026-12-31 · Advanced Solid Tumor
What this study did
NCT06199232 · Peking University
2024-01-23 – 2026-07-10 · Liver Metastasis Colon Cancer, ctDNA Genotype, MSS, Failed From Standard Treatment
What this study did
NCT06363708 · Zhongnan Hospital
2024-06-01 – 2026-06-30 · Endometrial Neoplasms
What this study did
NCT05963087 · Zhejiang Cancer Hospital
2023-08 – 2026-06 · Advanced Colorectal Cancer
What this study did
NCT05811793 · Second Affiliated Hospital of Nanchang University
2023-04-15 – 2025-12-30 · Glioblastoma
What this study did
NCT05058755 · Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
2021-09-17 – 2023-12-30 · Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type
What this study did
NCT05277675 · Southwest Hospital, China
2021-11-01 – 2023-10-30 · Hepatocellular Carcinoma Recurrent
What this study did
Used as active comparator (25)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (18)
Gastric Cancer
NCT07677293 · Peking University
2026-06-26 – 2028-12-31 · Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma
What this study did
Nasopharyngeal Carcinoma
NCT07925021 · CSPC Megalith Biopharmaceutical Co.,Ltd.
2026-11-06 – 2030-12-01 · Previously Systemic Treatment-Naive Recurrent or Metastatic Nasopharyngeal Carcinoma
What this study did
Non-Small Cell Lung Cancer
NCT07896005 · Suzhou Suncadia Biopharmaceuticals Co., Ltd.
2026-12 – 2032-03 · Non Small Cell Lung Cancer
What this study did
NCT07822542 · Jiangsu Hansoh Pharmaceutical Co., Ltd.
2026-10-31 – 2031-12-31 · Carcinoma, Non-Small-Cell Lung
What this study did
NCT07672223 · CSPC Megalith Biopharmaceutical Co.,Ltd.
2026-07-30 – 2031-11-30 · Non-small Cell Lung Cancer
What this study did
NCT07829549 · RemeGen Co., Ltd.
2026-10-10 – 2031-08 · Previously Untreated Locally Advanced (IIIB/IIIC) or Metastatic (IV) e Nsq NSCLC Without Actionable Genomic Alterations
What this study did
NCT07170995 · Suzhou Suncadia Biopharmaceuticals Co., Ltd.
2025-10-22 – 2030-12 · Advanced or Metastatic Non-small Cell Lung Cancer
What this study did
NCT07833202 · Shanghai Jeyou Pharmaceutical Co., Ltd.
2026-10 – 2030-09 · NSCLC
What this study did
NCT06416410 · Allist Pharmaceuticals, Inc.
2024-08-07 – 2030-08 · Advanced Non-squamous Non-small-cell Lung Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer
What this study did
NCT05690945 · Qilu Pharmaceutical Co., Ltd.
2023-02-15 – 2029-12 · Lung Cancer
What this study did
NCT07416474 · RemeGen Co., Ltd.
2026-04-03 – 2029-11-30 · Non-Small Cell Lung Cancer
What this study did
NCT07633873 · CSPC Megalith Biopharmaceutical Co.,Ltd.
2026-06-02 – 2029-05-30 · Non-Small Cell Lung Cancer
What this study did
NCT07383116 · Shanghai Huaota Biopharmaceutical Co., Ltd.
2026-01-15 – 2028-04-10 · Non Squamous Non-small Cell Lung Cancer
What this study did
NCT05840016 · Akeso
2023-08-17 – 2026-12-31 · Advanced Squamous Non Small Cell Lung Cancer
What this study did
NCT05990127 · Akeso
2023-11-14 – 2026-11-28 · Locally Advanced or Metastatic NSCLC
What this study did
NCT04746924 · BeiGene
2021-05-24 – 2026-03-18 · Non-small Cell Lung Cancer, NSCLC
What this study did
NCT05718167 · Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
2023-02 – 2025-10 · Advanced Squamous Non-Small Cell Lung Carcinoma
What this study did
Small Cell Lung Cancer
NCT07802821 · Qilu Pharmaceutical Co., Ltd.
2026-10-27 – 2030-06-15 · Extensive-stage Small Cell Lung Cancer
What this study did
Phase 2/3 (4)
Non-Small Cell Lung Cancer
NCT07662395 · Sinocelltech Ltd.
2026-05-09 – 2030-01-24 · Double Blind
What this study did
NCT07662811 · Shanghai Chest Hospital
2026-06-01 – 2029-12-31 · Non-Small Cell Lung Cancer
What this study did
Other / comorbidity
NCT07935369 · RemeGen Co., Ltd.
2026-11 – 2031-12-31 · Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
What this study did
Phase 2 (3)
Small Cell Lung Cancer
NCT06897579 · Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
2025-04-07 – 2026-04-15 · Extensive Stage Small Cell Lung Cancer
What this study did
Other / comorbidity
NCT07331155 · Nanjing Leads Biolabs Co.,Ltd
2026-02-26 – 2028-12-26 · Advanced Solid Tumour
What this study did
NCT07390383 · Nanjing Leads Biolabs Co.,Ltd
2026-04-13 – 2028-05-30 · Advanced Solid Tumour
What this study did
Appears in other studies (19)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 3 (3)
Esophageal Squamous Cell Carcinoma
NCT05919030 · Renmin Hospital of Wuhan University
2023-07-01 – 2027-07-01 · Esophageal Squamous Cell Carcinoma
What this study did
Non-Small Cell Lung Cancer
Other / comorbidity
NCT06206733 · AskGene Pharma, Inc.
2024-01-25 – 2028-12-30 · Gastroesophageal Junction Adenocarcinoma, Gastric Adenocarcinoma
What this study did
Phase 2 (11)
Esophageal Squamous Cell Carcinoma
Non-Small Cell Lung Cancer
NCT07264647 · Fondazione Ricerca Traslazionale
2025-03-27 – 2030-02-01 · Stage III NSCLC
What this study did
NCT06132698 · West China Hospital
2023-11-30 – 2026-06-30 · NSCLC Associated With Leptomeningeal Metastases
What this study did
NCT05519865 · Chipscreen Biosciences, Ltd.
2022-10-26 – 2024-11-18 · Non Small Cell Lung Cancer
What this study did
NCT05014815 · BeiGene
2021-11-16 – 2024-09-04 · Locally Advanced, Unresectable, or Metastatic Nonsmall Cell Lung Cancer (NSCLC), Nonsmall Cell Lung Cancer, Stage IIIB, Nonsmall Cell Lung Cancer, Stage IV
What this study did
Small Cell Lung Cancer
NCT07172412 · Tianjin Medical University Cancer Institute and Hospital
2025-11 – 2028-12 · Extensive Stage Lung Small Cell Cancer
What this study did
Other / comorbidity
NCT06420440 · Chen Xiaoping
2024-06-01 – 2027-12-31 · HCC
What this study did
NCT07157969 · Peking Union Medical College Hospital
2025-02-19 – 2027-06-30 · HCC - Hepatocellular Carcinoma
What this study did
NCT06695013 · Ruijin Hospital
2024-11-20 – 2027-03-20 · B-NHL, CART Therapy
What this study did
NCT06804850 · West China Hospital
2025-01-20 – 2026-06-30 · Head and Neck Cancer
What this study did
NCT07040956 · West China Hospital
2025-06-28 – 2026-06-26 · Head and Neck Squamous Cell Carcinoma, Low-dose Radiotherapy, Immunotherapy, Targeted Therapy
What this study did
Phase 1 (3)
Gastric Cancer
NCT06098898 · Base Therapeutics (Shanghai) Co., Ltd.
2023-11-01 – 2024-11-01 · Gastric Cancer
What this study did
Non-Small Cell Lung Cancer
NCT06097962 · Base Therapeutics (Shanghai) Co., Ltd.
2023-07-01 – 2028-07-01 · NSCLC
What this study did
NCT03732664 · Second Affiliated Hospital, Zhejiang University, School of Medicine
2018-10-01 – 2023-03-23 · High-Risk Resectable NSCLC
What this study did
Early phase / not applicable (2)
Esophageal Squamous Cell Carcinoma
NCT07067450 · Sichuan University
2025-07-20 – 2026-12-31 · Esophageal Squamous Cell Carcinoma (ESCC)
What this study did
Other / comorbidity
NCT05339581 · RenJi Hospital
2022-05-20 – 2024-05-31 · Liver Cancer, Liver Transplant; Complications, Hepatocellular Carcinoma, Portal Vein Thrombosis, Radiotherapy; Complications
What this study did

Competitive landscape

This mechanism is crowded: 26 other tracked programmes target it, none of them ahead of this one.

This drug's own stage for Non-Small Cell Lung Cancer: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Tislelizumab: this drugPhase 3Monoclonal antibodyPD-1Partial signalNo reviewed efficacy summary in this indication
Adagrasib (Krazati)ApprovedSmall moleculeKRAS G12CPartial signalFeatured results are non-efficacy only in this race
Afatinib (Gilotrif)ApprovedSmall moleculeEGFR/HER1, HER2, HER4Partial signal
NCT01121393: Progression-free Survival (Tumour assessment were performed at screening, week 6, 12, 18, 24, 30, 36, 42, 48 and then every 12 weeks until progression or death whichever occurs first up to week 168): Afatinib 40 Milligram (mg) 11.01 months (95% CI 9.66 to 13.73) vs Gemcitabine / Cisplatin Chemotherapy 5.59 months (95% CI 4.67 to 6.7)
NCT01523587: Progression-free Survival, Based on Central Independent Review as Determined by Response Evaluation Criteria in Solid Tumours 1.1 (First treatment administration up until cut off date of 02 March 2015 (up to 1058 days).): Afatinib 2.63 Months (95% CI 2 to 2.86) vs Erlotinib 1.94 Months (95% CI 1.87 to 2.1)
Alectinib (Alecensa)ApprovedSmall moleculeALKPartial signal
NCT02838420: Investigator-assessed progression-free survival: hazard ratio 0.22 (95% CI 0.13 to 0.38; p<0.0001), median not estimable with alectinib vs 11.1 months with crizotinib (ALESIA primary analysis, Lancet Respir Med 2019).
NCT02604342: Progression-Free Survival (PFS) Using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Investigator (Randomization to first documented disease progression, death from any cause, or study end (up to 33 months)): Experimental: Alectinib 10.9 months (95% CI 8.1 to 15.5) vs Active Comparator: Premetrexed/Docetaxel 1.4 months (95% CI 1.2 to 1.6)
Alymsys (bevacizumab-Maly)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
AmivantamabApprovedMultispecific antibodyEGFR x c-METPartial signal
NCT04487080: Progression-free survival by blinded independent central review (MARIPOSA, primary endpoint): amivantamab + lazertinib (Arm A, n=429) median 23.72 months (95% CI 19.12 to 27.66) vs osimertinib (Arm B, n=429) 16.59 months (95% CI 14.78 to 18.46); hazard ratio 0.70 (95% CI 0.58 to 0.85), log-rank p = 0.0002. ClinicalTrials.gov posted results.
NCT04988295: Main Study: Progression-free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR) (From randomization to either disease progression or death, whichever occurred first (up to 1 year 7 months)): Main Study: Arm A: Lazertinib + Amivantamab + Carboplatin + Pemetrexed (LACP/ACP-L) 8.31 months (95% CI 6.77 to 9.1) | Main Study: Arm C: Amivantamab + Carboplatin + Pemetrexed (ACP) 6.28 months (95% CI 5.55 to 8.41) vs Main Study: Arm B: Carboplatin + Pemetrexed (CP) 4.17 months (95% CI 4.04 to 4.44)
AtezolizumabApprovedMonoclonal antibodyPD-L1Partial signal
NCT03456063: IRF-assessed EFS, stage IIB-IIIB EGFR/ALK wild-type: HR 0.77 (95% CI 0.58-1.02), log-rank p=0.0704 missed
NCT02366143: Progression Free Survival (PFS), as Determined by the Investigator in Arm B Versus Arm C in the Teff-high WT Population and ITT-WT Population (Baseline until disease progression or death, whichever occurs first until data cut-off on 15 September 2017 (up to approximately 29 months)): Arm B (Atezolizumab+Bevacizumab+Paclitaxel + Carboplatin) — Teff-high WT Population: 11.3 Months (95% CI 9.1 to 13); ITT-WT Population: 8.3 Months (95% CI 7.7 to 9.8) vs Arm C (Bevacizumab+Paclitaxel+Carboplatin) — Teff-high WT Population: 6.8 Months (95% CI 5.9 to 7.4); ITT-WT Population: 6.8 Months (95% CI 6 to 7.1)
BAT1706 (Avzivi)ApprovedMonoclonal antibodyVEGF-APartial signal
NCT03329911: Overall response rate at week 18: 48.0% BAT1706 vs 44.5% EU-bevacizumab; risk ratio 1.08 (90% CI 0.94 to 1.24) and risk difference 0.03 (95% CI -0.04 to 0.11), both inside the pre-specified equivalence margins (Cancer Med 2023).
BevacizumabApprovedMonoclonal antibodyVEGF-A, Vascular Endothelial Growth Factor InhibitorPartial signal
NCT00806923: Progression-free survival: HR 0.75 (95% CI 0.64-0.87; P=0.0003) for bevacizumab 7.5 mg/kg + cisplatin/gemcitabine vs placebo + cisplatin/gemcitabine, and HR 0.85 (95% CI 0.73-1.00; P=0.0456) for bevacizumab 15 mg/kg vs placebo
NCT00021060: Overall survival, paclitaxel-carboplatin plus bevacizumab (n=434) vs paclitaxel-carboplatin alone (n=444): median 12.3 vs 10.3 months, hazard ratio for death 0.79, P = 0.003 (Sandler et al., NEJM 2006).
Bevacizumab-Awwb (MVASI)ApprovedMonoclonal antibodyVEGF-AReliable signal
NCT01966003: Objective response rate (central independent blinded review, RECIST v1.1), ABP 215 (bevacizumab-awwb, n=328) vs bevacizumab (n=314): 39.0% vs 41.7%; risk ratio 0.93 (2-sided 90% CI 0.80 to 1.09), inside the prespecified equivalence margin of 0.67 to 1.5 (CT.gov posted results).
BinimetinibApprovedSmall moleculeMEK1/2Weak signalNo reviewed efficacy summary in this indication
BrigatinibApprovedSmall moleculeALKPartial signal
NCT03596866: Progression-free Survival (PFS) as Assessed by Blinded Independent Review Committee (BIRC) Per RECIST v1.1 (Up to 33.8 months): Brigatinib 19.253 months vs Alectinib 19.187 months missed
NCT02737501: Progression-free Survival (PFS) (Up to end of study (Up to 56 months)): Randomized Phase: Brigatinib 90 mg QD/180 QD 24.016 months (95% CI 18.46 to 43.2) vs Randomized Phase: Crizotinib 250 mg BID 11.072 months (95% CI 9.13 to 13.01)
CapmatinibApprovedSmall moleculeMETWeak signal
NCT04427072: Progression-free Survival (PFS) Per Blinded Independent Review Committee (BIRC) Using RECIST v1.1 (From randomization to the date of first documented progression or death from any cause, whichever came first, assessed up to approximately 21 months): Capmatinib 6.1 months (95% CI 1.61 to 13.77) vs Docetaxel 4.1 months
NCT02414139: Overall response rate by independent review, single-arm cohorts: treatment-naive with MET mutation 68.3% (95% CI 55 to 79.7); pre-treated with MET mutation 44% (34.1 to 54.3); pre-treated MET copy number >= 10 29% (18.7 to 41.2); copy number < 4 6.7% (0.8 to 22.1).
CemiplimabApprovedMonoclonal antibodyPD-1Partial signal
NCT03088540: Overall Survival (OS) (Up to 94 months): Cemiplimab 23.4 months (95% CI 19.4 to 27.6) vs Chemotherapy 13.7 months (95% CI 11.2 to 16.2)
NCT03409614: Part 1: Overall Survival (OS) (Up to a maximum of 82.2 months): Part 1: Cemiplimab + Chemotherapy 15.9 months (95% CI 11.7 to 24.2) | Part 1: Cemiplimab+AbbrevChemo+Ipilimumab 20.1 months (95% CI 13.7 to 28.3) vs Part 1: Chemotherapy 13.9 months (95% CI 10 to 17.7)
CeritinibApprovedSmall moleculeALKPartial signal
NCT01828099: Progression Free Survival (PFS) by Blinded Independent Review Committee (BIRC) (From the date of randomization to the date of first radiologically documented disease progression or death due to any cause, up to approximately 34 months): Ceritinib 16.6 Months (95% CI 12.6 to 27.2) vs Chemotherapy 8.1 Months (95% CI 5.8 to 11.1)
NCT01828112: Progression Free Survival (PFS) Per Blinded Independent Review Committee (BIRC) (From the date of randomization to the date of first radiologically documented disease progression or death due to any cause up to approximately 24 months): Ceritinib 5.4 months (95% CI 4.1 to 6.9) vs Chemotherapy 1.6 months (95% CI 1.4 to 2.8)
CrizotinibApprovedSmall moleculeALK, ROS1, MET/HGFR, and RONPartial signal
NCT01639001: Progression-Free Survival (PFS) Based on IRR by Treatment Arm (Randomization to objective progression, death or last tumor assessment without progression before any additional anti-cancer therapy (whichever occurred first, assessed up to 33 months)): Crizotinib 11.1 Months (95% CI 8.3 to 12.6) vs Chemotherapy 6.8 Months (95% CI 5.7 to 7)
NCT01154140: Progression-Free Survival (PFS) Based on IRR (Randomization to objective progression, death or last tumor assessment without progression before any additional anti-cancer therapy (up to 35 months)): Crizotinib 10.9 months (95% CI 8.3 to 13.9) | Chemotherapy 7 months (95% CI 6.8 to 8.2)
DabrafenibApprovedSmall moleculeBRAF V600E/V600K/V600D (also wild-type BRAF/CRAF)Weak signal
NCT04452877: Objective response rate (central and investigator assessment): 75% (95% CI 50.9-91.3%). Disease control rate (central independent review): 95% (95% CI 75.1-99.9%).
NCT01336634: Overall Response Rate (ORR) (From study treatment start date until first documented complete response or partial response, assessed up to approximately 50 months): Cohort A (Dabrafenib Monotherapy) 27/78 | Cohort B - Double Combination (Dabrafenib+Trametinib) mBRAF V600E: DAB 150MG BID, TRA 2mG QD 39/57 | Cohort C - Double Combination (Dabrafenib+Trametinib) Naive mBRAF V600E: DAB 150MG BID, TRA 2mG QD 23/36 | Crossover - Double Combination (Dabrafenib+Trametinib): DAB 150MG BID, TRA 2mG QD 4/20
Dacomitinib PF-00299804
ApprovedUS marketing discontinued
Small moleculeEGFR/HER1, HER2, HER4Partial signal
NCT01774721: Progression Free Survival (PFS) Based on Independent Radiologic Central (IRC) Review (Day 28 of Cycle 1, Cycle 2 then every 8 weeks until disease progression or death due to any cause, whichever occurred first (up to 48 months)): Dacomitinib 14.7 months (95% CI 11.1 to 16.6) vs Gefitinib 9.2 months (95% CI 9.1 to 11)
NCT01000025: Overall Survival (42 Months): PF-00299804 6.83 Months (95% CI 6.08 to 7.49) vs Placebo 6.31 Months (95% CI 5.32 to 7.52) missed
Datopotamab DeruxtecanApprovedAntibody–drug conjugateTROP2Partial signal
NCT04656652: Dual primaries vs docetaxel: progression-free survival 4.4 vs 3.7 months (hazard ratio 0.75; 95% CI 0.62 to 0.91; P=.004); overall survival 12.9 vs 11.8 months (hazard ratio 0.94; 95% CI 0.78 to 1.14; P=.530) (TROPION-Lung01, J Clin Oncol 2025).
NCT04484142: Percentage of Participants With Objective Response Rate (ORR) Based on Blinded Independent Central Review (BICR) (From baseline until disease progression, death, or other protocol defined reason, up to approximately 24 months.): Dato DXd 6.0 mg/kg Q3W 35.8% (95% CI 27.8 to 44.4)
Docetaxel (Taxotere)ApprovedSmall moleculeMicrotubules (tubulin)not yet gradedNo reviewed efficacy summary in this indication
DurvalumabApprovedMonoclonal antibodyPD-L1Reliable signal
NCT02125461: Progression Free Survival Based on Blinded Independent Central Review (BICR) According to Response Evaluation Criteria in Solid Tumors (RECIST 1.1) (Tumor scans performed at baseline then every ~8 weeks up to 48 weeks, then every ~12 weeks thereafter until confirmed disease progression. Assessed until 13 Feb 2017 DCO; up to a maximum of approximately 3 years.): Durvalumab (MEDI4736) 16.8 Months (95% CI 13 to 18.1) vs Placebo 5.6 Months (95% CI 4.6 to 7.8)
NCT03519971: Progression-Free Survival (PFS) (Tumour scans performed at screening, 16 weeks ±1 week after randomization, then every 8 weeks ±1 week up to 48 weeks, and then every 12 weeks ±1 week thereafter until confirmed PD. Assessed up to the DCO date (a maximum of approximately 1988 days).): Durvalumab + SoC CRT 13.8 months (95% CI 9.5 to 16.9) vs Placebo + SoC CRT 9.4 months (95% CI 7.5 to 16.6) missed
EncorafenibApprovedSmall moleculeBRAF V600EWeak signal
NCT03915951: Percentage of Participants With Confirmed Objective Response (OR) as Determined by Independent Radiology Review (IRR) (From date of the first dose of study intervention until documented progressive disease (PD) or start of new anticancer therapy (up to 36 months)): Treatment-Naive 74.6% (95% CI 61.6 to 85) | Previously Treated 46.2% (95% CI 30.1 to 62.8)
Ensartinib (Ensacove)ApprovedSmall moleculeALKPartial signal
NCT02767804: eXalt3 (NCT02767804), primary endpoint PFS: ensartinib median PFS 25.8 months vs crizotinib 12.7 months; HR 0.51 (95% CI 0.35-0.72); p<.001.
EntrectinibApprovedSmall moleculeROS1/NTRKnot yet gradedNo reviewed efficacy summary in this indication
ErlotinibApprovedSmall moleculeEGFRPartial signal
NCT00446225: Primary endpoint, progression-free survival: hazard ratio 0.42 (95% CI 0.27 to 0.64), p=0.0001, erlotinib vs platinum doublet chemotherapy in EGFR-mutant NSCLC (CT.gov posted results).
GefitinibApprovedSmall moleculeEGFRPartial signal
NCT00020709: Overall survival (maintenance phase, SWOG S0023): median survival 23 months with gefitinib (n=118) vs 35 months with placebo (n=125), two-sided P=.013 missed
Gemcitabine
ApprovedUS marketing discontinued
Small moleculeribonucleotide reductase / DNA polymerase (dCTP competition)Partial signal
NCT00003589: Median overall survival: paclitaxel-cisplatin (arm A) 8.1 months vs gemcitabine-cisplatin (arm B) 8.9 months vs paclitaxel-gemcitabine (arm C) 6.7 months; response rates 31.8% / 36.6% / 27.7% respectively
IpilimumabApprovedMonoclonal antibodyCTLA-4 antagonistPartial signal
NCT01285609: Median overall survival: 13.37 months with ipilimumab plus paclitaxel/carboplatin (95% CI 11.76 to 14.78) vs 12.42 months with placebo plus paclitaxel/carboplatin (95% CI 11.6 to 13.63). missed
Jobevne (bevacizumab-Nwgd)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
LarotrectinibApprovedSmall moleculeTRK (TRKA/TRKB/TRKC, encoded by NTRK1/NTRK2/NTRK3 gene fusions)not yet gradedNo reviewed efficacy summary in this indication
LazertinibApprovedSmall moleculeEGFRPartial signal
NCT04487080: Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR) (From randomization to either disease progression or death whichever occurs first (up to 32.8 months)): Experimental: Arm A (Open-label): Amivantamab + Lazertinib 23.72 Months (95% CI 19.12 to 27.66) | Experimental: Arm C (Double-blind): Lazertinib+Placebo Matching Osimertinib 18.46 Months (95% CI 14.75 to 20.11) vs Active Comparator: Arm B (Double-blind): Osimertinib+Placebo Matching Lazertinib 16.59 Months (95% CI 14.78 to 18.46)
NCT04988295: Main Study: Progression-free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR) (From randomization to either disease progression or death, whichever occurred first (up to 1 year 7 months)): Main Study: Arm A: Lazertinib + Amivantamab + Carboplatin + Pemetrexed (LACP/ACP-L) 8.31 months (95% CI 6.77 to 9.1) | Main Study: Arm C: Amivantamab + Carboplatin + Pemetrexed (ACP) 6.28 months (95% CI 5.55 to 8.41) vs Main Study: Arm B: Carboplatin + Pemetrexed (CP) 4.17 months (95% CI 4.04 to 4.44)
LorlatinibApprovedSmall moleculeALK / ROS1Partial signalNo reviewed efficacy summary in this indication
Nab-PaclitaxelApprovedSmall moleculeMicrotubulesPartial signal
NCT00540514: Percentage of Participants Who Achieved an Objective Confirmed Complete Response or Partial Response by Blinded Radiology Assessment (Objective response was evaluated every 6 weeks until progression or new anti-cancer therapy initiation, up to 22 months.): Albumin-bound Paclitaxel + Carboplatin 33% (95% CI 28.6 to 36.7) vs Paclitaxel + Carboplatin 25% (95% CI 21.2 to 28.5)
NecitumumabApprovedMonoclonal antibodyEpidermal growth factor receptor (EGFR)Partial signal
NCT00981058: Overall Survival Time (OS) (Randomization to Death from Any Cause (Up to 31 Months)): Necitumumab + Gemcitabine + Cisplatin 11.5 Months (95% CI 10.4 to 12.6) vs Gemcitabine + Cisplatin 9.9 Months (95% CI 8.9 to 11.1)
NCT00982111: Overall Survival Time (OS) (Randomization to Death from Any Cause (Up to 31.6 Months)): Necitumumab + Pemetrexed + Cisplatin 11.3 Months (95% CI 9.5 to 13.4) vs Pemetrexed + Cisplatin 11.5 Months (95% CI 10.1 to 13.1) missed
NivolumabApprovedMonoclonal antibodyPD-1Partial signal
NCT01673867: Overall Survival (OS) Time in Months for All Randomized Participants at Primary Endpoint (Randomization until 413 deaths, up to March 2015 (approximately 29 months)): Nivolumab 12.19 Months (95% CI 9.66 to 14.98) vs Docetaxel 9.36 Months (95% CI 8.05 to 10.68)
NCT01642004: Overall Survival (OS) Time in Months for All Randomized Participants at Primary Endpoint (Randomization until 199 deaths, up to November 2014, approximately 25 months): Nivolumab 9.23 months (95% CI 7.33 to 13.27) vs Docetaxel 6.01 months (95% CI 5.13 to 7.33)
Opdivo QvantigApprovedMonoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
Osimertinib (Tagrisso)ApprovedSmall moleculeEGFRPartial signal
NCT02151981: Progression Free Survival (PFS) by Investigator Assessment (RECIST tumour assessments every 6 weeks from randomisation until objective disease progression up to 19 months (at the time of the primary PFS analysis).): Osimertinib 80mg 10.1 Months (95% CI 8.3 to 12.3) | Chemotherapy 4.4 Months (95% CI 4.2 to 5.6)
PembrolizumabApprovedMonoclonal antibodyPD-1Partial signal
NCT02142738: Progression Free Survival (PFS) Rate at Month 6 (Month 6): Pembrolizumab 62.1% (95% CI 53.8 to 69.4) vs SOC Chemotherapy 50.3% (95% CI 41.9 to 58.2)
NCT01905657: Overall Survival (OS) (Through pre-specified database cutoff date of 30 Sep 2015 (Up to approximately 24 months)): Pembrolizumab 2 mg/kg — Strongly PD-L1 Positive: 14.9 Months; All PD-L1 Positive: 10.4 Months (95% CI 9.4 to 11.9) | Pembrolizumab 10 mg/kg — Strongly PD-L1 Positive: 17.3 Months; All PD-L1 Positive: 12.7 Months (95% CI 10 to 17.3) vs Docetaxel 75 mg/m^2 — Strongly PD-L1 Positive: 8.2 Months (95% CI 6.4 to 10.7); All PD-L1 Positive: 8.5 Months (95% CI 7.5 to 9.8)
Pembrolizumab Berahyaluronidase Alfa (Keytruda Qlex)ApprovedMonoclonal antibodyPD-1Partial signalFeatured results are non-efficacy only in this race
Pemetrexed (Alimta)ApprovedSmall moleculeThymidylate synthase (TS), dihydrofolate reductase (DHFR), GARFTPartial signal
NCT00789373: Investigator-assessed Objective Progression-free Survival (PFS) (Date of randomization to the date of measured PD or date of death from any cause (up to 19.3 months)): Pemetrexed + Cisplatin Followed by Maintenance Pemetrexed 4.11 months (95% CI 3.15 to 4.57) | Pemetrexed + Cisplatin Followed by Placebo 2.83 months (95% CI 2.6 to 3.12)
NCT00102804: Progression-Free Survival (PFS) Time (Randomization to measured PD or death from any cause (up to 41 months)): Pemetrexed and BSC 4.27 months (95% CI 4.07 to 4.73) | Placebo and BSC 2.6 months (95% CI 1.68 to 2.83)
Porfimer SodiumApprovedSmall moleculePhotoactivated radicalsWeak signalFeatured results are safety and non-efficacy only in this race
PralsetinibApprovedSmall moleculeRETPartial signal
NCT04222972: Arm A vs Arm B: Treatment Period: Progression-free Survival (PFS) (Up to approximately 50 months): Arm B: Treatment Period- Pralsetinib 18.7 months (95% CI 11.1 to 25.2) vs Arm A: Treatment Period- SOC 9 months (95% CI 7.1 to 11.5)
NCT03037385: Phase 2 confirmed overall response rate by blinded central review (RECIST 1.1), pralsetinib 400 mg once daily, single arm: RET fusion-positive NSCLC after platinum 63.1% (95% CI 54.2 to 71.4; n=130); treatment-naive RET fusion-positive NSCLC 78.3% (95% CI 69.2 to 85.7; n=106).
RamucirumabApprovedMonoclonal antibodyVEGFR2Partial signal
NCT05633602: Pragmatica-Lung (NCT05633602), primary endpoint overall survival: ramucirumab plus pembrolizumab median OS 10.1 months vs SOC 10.0 months; HR 1.04 (95% CI 0.88-1.22); p=.66. missed
NCT01168973: Overall survival: ramucirumab plus docetaxel 10.5 months vs placebo plus docetaxel 9.1 months (HR 0.86, 95% CI 0.75-0.98; p=0.023), n=1253 (Garon et al., Lancet 2014, REVEL).
RepotrectinibApprovedSmall moleculeROS1/NTRKnot yet gradedNo reviewed efficacy summary in this indication
Rybrevant Faspro (amivantamab And Hyaluronidase-Lpuj)ApprovedMultispecific antibodyEGFR x c-METnot yet gradedNo reviewed efficacy summary in this indication
Selpercatinib (Retevmo)ApprovedSmall moleculeRETPartial signal
NCT04819100: Investigator-assessed event-free survival, stage II-IIIA (primary): 2-year EFS 92% with selpercatinib vs 61% with placebo; HR 0.17 (95% CI 0.06 to 0.51), P<0.001 (Wu et al., N Engl J Med 2026)
NCT04194944: PFS by blinded independent central review (pembrolizumab-eligible population): median 24.84 months with selpercatinib (95% CI 16.89 to not estimable) vs 11.17 months with platinum-pemetrexed plus pembrolizumab (95% CI 8.77 to 16.76); HR 0.465 (95% CI 0.309 to 0.699), p=0.0002
Sevabertinib (Hyrnuo)ApprovedSmall moleculeEGFR/HER2Weak signalNo reviewed efficacy summary in this indication
SotorasibApprovedSmall moleculeKRAS G12CPartial signal
NCT04303780: Progression-free Survival (PFS) (Baseline up to primary analysis data cut-off date (02 August 2022); max time on study as of primary analysis data cut off was 24.3 months): AMG 510 5.62 months (95% CI 4.27 to 7.75) vs Docetaxel 4.47 months (95% CI 3.02 to 5.68)
NCT03600883: NSCLC cohort (FDA label section 14, single arm): objective response rate 36% (95% CI 28 to 45) by blinded independent central review in 124 patients given sotorasib 960 mg once daily; complete response 2%, partial response 35%; median duration of response 10 months (range 1.3+ to 11.1); 58% of responders had a response lasting 6 months or more.
Sunvozertinib (Zegfrovy)ApprovedSmall moleculeEGFRnot yet gradedNo reviewed efficacy summary in this indication
TaletrectinibApprovedSmall moleculeROS1not yet gradedNo reviewed efficacy summary in this indication
Tecentriq Hybreza (atezolizumab And Hyaluronidase-Tqjs)ApprovedMonoclonal antibodyPD-L1Partial signalNo reviewed efficacy summary in this indication
Telisotuzumab VedotinApprovedAntibody–drug conjugateMETnot yet gradedNo reviewed efficacy summary in this indication
Tepotinib (Tepmetko)ApprovedSmall moleculeMETWeak signal
NCT02864992: ORR by independent review 46% (95% CI 36–57) in 99 patients with at least 9 months of follow-up; median duration of response 11.1 months
TrametinibApprovedSmall moleculeMEK1/2Partial signal
NCT01336634: Overall Response Rate (ORR) (From study treatment start date until first documented complete response or partial response, assessed up to approximately 50 months): Cohort A (Dabrafenib Monotherapy) 27/78 | Cohort B - Double Combination (Dabrafenib+Trametinib) mBRAF V600E: DAB 150MG BID, TRA 2mG QD 39/57 | Cohort C - Double Combination (Dabrafenib+Trametinib) Naive mBRAF V600E: DAB 150MG BID, TRA 2mG QD 23/36 | Crossover - Double Combination (Dabrafenib+Trametinib): DAB 150MG BID, TRA 2mG QD 4/20
Trastuzumab DeruxtecanApprovedAntibody–drug conjugateHER2Weak signal
NCT04644237: Percentage of Participants With Confirmed Objective Response Rate by Blinded Independent Central Review Following Intravenous Administration of Trastuzumab Deruxtecan in Participants With Metastatic Non-small Cell Lung Cancer (9 months after the last participant is randomized to data cut off, up to approximately 21 months): Trastuzumab Deruxtecan 5.4 mg/kg 50% (95% CI 39.9 to 60.1) | Trastuzumab Deruxtecan 6.4 mg/kg 56% (95% CI 41.3 to 70)
TremelimumabApprovedMonoclonal antibodyCTLA-4Partial signal
NCT02453282: Overall Survival (OS); PD-L1 (TC >=25%) Analysis Set Population, Durvalumab Monotherapy Vs SoC Chemotherapy and Durvalumab + Tremelimumab Vs SoC Chemotherapy (From baseline (Day 1, Week 0) until death due to any cause, assessed up to the data cut-off date (a maximum of approximately 3 years).): Durvalumab + Tremelimumab 11.9 months (95% CI 9 to 17.7) vs Durvalumab Monotherapy 16.3 months (95% CI 12.2 to 20.8) | SoC Chemotherapy 12.9 months (95% CI 10.5 to 15) missed
NCT02352948: Overall Survival (OS) (From randomization (Day 1) until death due to any cause, approximately 36 months): Sub-study B: Durvalumab+Tremelimumab 11.5 months (95% CI 8.7 to 14.1) vs Sub-study A: Durvalumab 11.7 months (95% CI 8.2 to 17.4) | Sub-study A: SoC 6.8 months (95% CI 4.9 to 10.2) | Sub-study B: SoC 8.7 months (95% CI 6.5 to 11.7) missed
Vegzelma (bevacizumab-Adcd)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Zenocutuzumab (Bizengri)ApprovedMultispecific antibodyHER2; HER3 (blocks NRG1 binding to HER3)not yet gradedNo reviewed efficacy summary in this indication
ZidesamtinibApprovedSmall moleculeROS1not yet gradedNo reviewed efficacy summary in this indication
Zirabev (bevacizumab-Bvzr)ApprovedMonoclonal antibodyVEGF-AReliable signal
NCT02364999: Objective Response Rate (ORR) by Week 19 (25 weeks): PF-06439535 45.3% (95% CI 40.01 to 50.57) vs Bevacizumab-EU 44.6% (95% CI 39.4 to 49.89)
Zongertinib (Hernexeos)ApprovedSmall moleculeHER2 Mutant-selectivenot yet gradedNo reviewed efficacy summary in this indication
7MW3711Phase 3Antibody–drug conjugateB7-H3not yet gradedNo reviewed efficacy summary in this indication
Abp 234Phase 3Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
AdebrelimabPhase 3Monoclonal antibodyPD-L1not yet gradedNo reviewed efficacy summary in this indication
Aglatimagene BesadenovecPhase 3Gene therapy / editingHerpes simplex virus thymidine kinase (HSV-tk) gene productnot yet gradedNo reviewed efficacy summary in this indication
AlmonertinibPhase 3Small moleculeEGFRPartial signal
NCT04500717: ACROSS 2 in stage IIIB-IV NSCLC with EGFR sensitizing mutations and tumor suppressor gene mutations: median PFS 19.78 months (aumolertinib plus carboplatin/pemetrexed) versus 16.53 months (aumolertinib monotherapy); HR 0.55 (95% CI: 0.339-0.910; p=0.0205).
AndamertinibPhase 3Small moleculeEGFRnot yet gradedNo reviewed efficacy summary in this indication
BAT3306Phase 3Monoclonal antibodyPD-1Partial signalNo reviewed efficacy summary in this indication
CamrelizumabPhase 3Monoclonal antibodyPD-1Partial signal
NCT03134872: Primary 1, BICR-assessed PFS in all treated randomized patients (interim analysis): median 11.3 vs 8.3 months, camrelizumab plus carboplatin and pemetrexed vs carboplatin and pemetrexed; HR 0.60 (95% CI 0.45 to 0.79); one-sided p=0.0001, met. Primary 2, BICR-assessed PFS in PD-L1-positive patients: no confirmatory test reported.
CT-P51Phase 3Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
DostarlimabPhase 3Monoclonal antibodyPD-1Partial signal
NCT04655976: Overall Survival (OS) (Arm A Versus Arm C) (Up to approximately 234 weeks): Cobolimab + Dostarlimab + Docetaxel (Arm A) 11.9 Months (95% CI 10.6 to 14.2) vs Docetaxel (Arm C) 11.3 Months (95% CI 9.5 to 13.9) missed
EnlonstobartPhase 3Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
Iparomlimab (QL1604)
Phase 3(overall)
Monoclonal antibodyPD-1
not yet graded(overall)
No reviewed efficacy summary in this indication
IzalontamabPhase 3Multispecific antibodyEGFR + HER3not yet gradedNo reviewed efficacy summary in this indication
Izalontamab BrengitecanPhase 3Antibody–drug conjugateEGFR + HER3not yet gradedNo reviewed efficacy summary in this indication
MB12Phase 3Monoclonal antibodyPD-1Partial signalNo reviewed efficacy summary in this indication
Obrixtamig
Phase 3(overall)
Multispecific antibodyDLL3 (Delta-like ligand 3) x CD3not yet gradedNo reviewed efficacy summary in this indication
PenpulimabPhase 3Monoclonal antibodyPD-1Reliable signal
NCT03866993: Primary 1, IRRC-assessed PFS in the ITT population (final analysis): median 7.6 months (95% CI 6.8 to 9.6) penpulimab + chemotherapy vs 4.2 months (95% CI 4.2 to 4.3) placebo + chemotherapy; HR 0.43 (95% CI 0.33 to 0.56); p<0.0001, met. Primary 2, IRRC-assessed PFS in the PD-L1-positive subgroup: median 8.1 vs 4.2 months; HR 0.37 (95% CI 0.27 to 0.52); p<0.0001, met.
PumitamigPhase 3Multispecific antibodyPD-L1 and VEGF-Anot yet gradedNo reviewed efficacy summary in this indication
RetifanlimabPhase 3Monoclonal antibodyPD-1Reliable signal
NCT04205812: Overall Survival (up to 39.1 months): Retifanlimab + Chemotherapy 18.1 months (95% CI 16.2 to 21) vs Placebo + Chemotherapy 13.4 months (95% CI 11 to 16.7)
Retlirafusp AlfaPhase 3Multispecific antibodyPD-L1 and TGF-beta (TGF-βRII trap)Partial signalNo reviewed efficacy summary in this indication
RilvegostomigPhase 3Multispecific antibodyPD-1 and TIGITnot yet gradedNo reviewed efficacy summary in this indication
Risvutatug RezetecanPhase 3Antibody–drug conjugateB7-H3not yet gradedNo reviewed efficacy summary in this indication
S-1Phase 3Small moleculeThymidylate synthase (via 5-FU, released from tegafur) and dihydropyrimidine dehydrogenase (inhibited by gimeracil)not yet gradedNo reviewed efficacy summary in this indication
SerplulimabPhase 3Monoclonal antibodyPD-1Weak signal
NCT04033354: At the final analysis, serplulimab plus chemotherapy significantly improved median OS compared to placebo plus chemotherapy (HR 0.73, 95% CI 0.58-0.93; p=0.010); at the second interim analysis, the PFS benefit was maintained in the serplulimab-chemotherapy group (HR 0.53, 95% CI 0.42-0.67).
NCT03952403: Final analysis in nonsquamous NSCLC: median overall survival reached 26.8 months for Hetronifly (serplulimab) plus chemotherapy compared with 20.3 months for chemotherapy alone, a 34% reduction in the risk of death (HR=0.66, 95% CI: 0.52-0.83, P<0.001); median PFS was 11.0 months in Group B versus 5.7 months in the chemotherapy-only arm. No statistical difference was observed for Group A compared to Group B (HR=1.12, p=0.3628).
SintilimabPhase 3Monoclonal antibodyPD-1Partial signal
NCT03150875: Overall survival: sintilimab median 11.79 vs docetaxel 8.25 months (HR 0.74, 95% CI 0.56 to 0.96, P=0.025) (ORIENT-3, Cancer Commun 2022).
NCT03607539: Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as Assessed by Independent Radiographic Review Committee (IRRC) (Trough Database Cutoff Date of 15-Nov-2019 (Up to approximately 16 months)): Sintilimab Combination 8.9 Months (95% CI 7.1 to 11.3) vs Placebo Combination 5 Months (95% CI 4.8 to 6.2)
ToripalimabPhase 3Monoclonal antibodyPD-1Reliable signal
NCT04158440: Primary, investigator-assessed EFS in the stage III population (interim analysis, n=404): median not estimable vs 15.1 months, toripalimab + chemotherapy vs placebo + chemotherapy; HR 0.40 (95% CI 0.28 to 0.57); P<.001, met. Primary, BIPR-assessed MPR rate in the stage III population: 48.5% vs 8.4% (difference 40.2%, 95% CI 32.2% to 48.1%; P<.001), met. Primaries, EFS and MPR rate in the stage II-III population (final analysis): the sponsor states both met the pre-defined efficacy boundary; figures not yet published, met.
NCT03856411: Median PFS: 8.4 months (toripalimab plus chemotherapy) vs 5.6 months (placebo plus chemotherapy); HR 0.49 (95% CI 0.39-0.61), P<0.0001
Trastuzumab RezetecanPhase 3Antibody–drug conjugateHER2not yet gradedNo reviewed efficacy summary in this indication
BudigalimabPhase 2/3Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
SasanlimabPhase 2/3Monoclonal antibodyPD-1Partial signalFeatured results are dose-finding only in this race
AL8326Phase 2Small moleculeAurora B / FGFR / VEGFR (multi-kinase)not yet gradedNo reviewed efficacy summary in this indication
BalstilimabPhase 2Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
Disitamab VedotinPhase 2Antibody–drug conjugateHER2Weak signalNo reviewed efficacy summary in this indication
Ifinatamab DeruxtecanPhase 2Antibody–drug conjugateB7-H3not yet gradedNo reviewed efficacy summary in this indication
SHR-3045
Phase 2(overall)
UndisclosedPD-1
not yet graded(overall)
No reviewed efficacy summary in this indication
TagitanlimabPhase 2Monoclonal antibodyPD-L1not yet gradedNo reviewed efficacy summary in this indication
ZanidatamabPhase 2Multispecific antibodyHER2not yet gradedNo reviewed efficacy summary in this indication
ALE.P02Phase 1/2Antibody–drug conjugateClaudin-1 (CLDN1)not yet gradedNo reviewed efficacy summary in this indication
ASP546CPhase 1/2Antibody–drug conjugateClaudin 18.2 (CLDN18.2)not yet gradedNo reviewed efficacy summary in this indication
CetrelimabPhase 1/2Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
IOV-4001Phase 1/2Cell therapyPD-1not yet gradedNo reviewed efficacy summary in this indication
OSE-279Phase 1/2Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
Quaratusugene Ozeplasmid (Reqorsa)Phase 1/2Gene therapy / editingTUSC2 (tumor suppressor gene replacement)not yet gradedNo reviewed efficacy summary in this indication
Tambotatug PelitecanPhase 1/2Antibody–drug conjugateB7-H3not yet gradedNo reviewed efficacy summary in this indication
AfivastobartPhase 1Monoclonal antibodyCD39 (ENTPD1)not yet gradedNo reviewed efficacy summary in this indication
Bmab1700
Phase 1(overall)
Monoclonal antibodyPD-1
not yet graded(overall)
No reviewed efficacy summary in this indication
CRX100Phase 1Cell therapyCell-based oncolytic virus immunotherapynot yet gradedNo reviewed efficacy summary in this indication
ONO-4578Phase 1Small moleculeProstaglandin E2 receptor 4 (EP4)not yet gradedNo reviewed efficacy summary in this indication

Large race: only the 107 furthest-along competitors are listed; 506 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Upcoming events

(227 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Tislelizumab to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (38)
November 2026 (5)
Phase 2Hepatocellular Carcinoma (HCC)Not yet recruiting
Est. primary completion 2026-11 · NCT07829926 · CT.gov ↗
What to watch
Phase 2MSI-H/dMMR Solid TumorsRecruiting
Est. primary completion 2026-11 · NCT03736889 · CT.gov ↗
What to watch
Phase 3Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2026-11 · NCT06704620 · CT.gov ↗
What to watch
Phase 2Head and Neck Squamous Cell CarcinomaRecruiting
Est. primary completion 2026-11-30 · NCT06725498 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2026-11-30 · NCT06749886 · CT.gov ↗
What to watch
December 2026 (33)
Phase 1Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2026-12 · NCT05238883 · CT.gov ↗
What to watch
Phase 1Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2026-12 · NCT05789069 · CT.gov ↗
What to watch
Phase 2Triple-negative Breast Cancer, Bone MetastasesRecruiting
Est. primary completion 2026-12 · NCT06538896 · CT.gov ↗
What to watch
Phase 2NK/T Cell LymphomaRecruiting
Est. primary completion 2026-12 · NCT07000617 · CT.gov ↗
What to watch
Phase 2Thymic Carcinoma, ThymomaRecruiting
Est. primary completion 2026-12 · NCT06838910 · CT.gov ↗
What to watch
Phase 2Patients With Initially Unresectable MSS-type Advanced Colorectal Cancer With Liver and/or Lung and Peritoneal MetastasisActive not recruiting
Est. primary completion 2026-12 · NCT07512674 · CT.gov ↗
What to watch
Phase 2Bladder CancerActive not recruiting
Est. primary completion 2026-12 · NCT05531123 · CT.gov ↗
What to watch
Phase 3Nasopharyngeal CarcinomaRecruiting
Est. primary completion 2026-12 · NCT06177301 · CT.gov ↗
What to watch
Early phase / not applicableHCC - Hepatocellular Carcinoma, TP53 Gene Mutation, Unresectable, Resistant CancerNot yet recruiting
Est. primary completion 2026-12 · NCT07535840 · CT.gov ↗
What to watch
Phase 1/2Advanced Malignant Solid TumorsRecruiting
Est. primary completion 2026-12-01 · NCT06499350 · CT.gov ↗
What to watch
Phase 2Recurrent Hepatocellular CarcinomaRecruiting
Est. primary completion 2026-12-01 · NCT04615143 · CT.gov ↗
What to watch
Phase 2Rectal Cancer PatientsRecruiting
Est. primary completion 2026-12-01 · NCT06647680 · CT.gov ↗
What to watch
Phase 2/3Locally Advanced Rectal CarcinomaRecruiting
Est. primary completion 2026-12-01 · NCT06312982 · CT.gov ↗
What to watch
Phase 1Gastric CancerRecruiting
Est. primary completion 2026-12-24 · NCT05768932 · CT.gov ↗
What to watch
Phase 2DLBCLActive not recruiting
Est. primary completion 2026-12-28 · NCT05253118 · CT.gov ↗
What to watch
Phase 2Head and Neck Squamous Cell Carcinoma, Head and Neck Cancer, HNSCC, Head Cancer NeckNot yet recruiting
Est. primary completion 2026-12-30 · NCT06366945 · CT.gov ↗
What to watch
Phase 2Intrahepatic CholangiocarcinomaRecruiting
Est. primary completion 2026-12-30 · NCT06664021 · CT.gov ↗
What to watch
Phase 2Upper Tract Urothelial Carcinoma, Neoadjuvant Therapy, PD-1 Inhibitor, Nab-paclitaxelRecruiting
Est. primary completion 2026-12-30 · NCT07126119 · CT.gov ↗
What to watch
Phase 2Renal Pelvic Carcinoma, Tislelizumab, PD-1 Inhibitor, Kidney-sparing, Nab-paclitaxelRecruiting
Est. primary completion 2026-12-30 · NCT07233252 · CT.gov ↗
What to watch
Phase 2Colorectal CancerActive not recruiting
Est. primary completion 2026-12-30 · NCT06356597 · CT.gov ↗
What to watch
Phase 2Neoadjuvant ImmunotherapyRecruiting
Est. primary completion 2026-12-30 · NCT05837806 · CT.gov ↗
What to watch
Phase 1Small Cell Lung CancerRecruiting
Est. primary completion 2026-12-31 · NCT07413042 · CT.gov ↗
What to watch
Phase 2Gastric CancerNot yet recruiting
Est. primary completion 2026-12-31 · NCT06238167 · CT.gov ↗
What to watch
Phase 2LymphomaRecruiting
Est. primary completion 2026-12-31 · NCT05477264 · CT.gov ↗
What to watch
Phase 2Esophagus CancerRecruiting
Est. primary completion 2026-12-31 · NCT06430658 · CT.gov ↗
What to watch
Phase 2Nasopharyngeal CarcinomaRecruiting
Est. primary completion 2026-12-31 · NCT06676722 · CT.gov ↗
What to watch
Phase 2Gastric CancerNot yet recruiting
Est. primary completion 2026-12-31 · NCT07304258 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2026-12-31 · NCT07330037 · CT.gov ↗
What to watch
Phase 2Biliary Tract CarcinomaRecruiting
Est. primary completion 2026-12-31 · NCT05668884 · CT.gov ↗
What to watch
Phase 2Small Cell Lung CancerRecruiting
Est. primary completion 2026-12-31 · NCT06536868 · CT.gov ↗
What to watch
Phase 3Advanced CholangiocarcinomaRecruiting
Est. primary completion 2026-12-31 · NCT05823311 · CT.gov ↗
What to watch
Phase 3Gastric CancerActive not recruiting
Est. primary completion 2026-12-31 · NCT06939439 · CT.gov ↗
What to watch
Phase 3B-cell MalignanciesActive not recruiting
Est. primary completion 2026-12-31 · NCT04170283 · CT.gov ↗
What to watch
2027 (92)
January 2027 (6)
Phase 1/2Colorectal CarcinomaNot yet recruiting
Est. primary completion 2027-01-01 · NCT07025850 · CT.gov ↗
What to watch
Phase 2Small Cell Lung CancerNot yet recruiting
Est. primary completion 2027-01-15 · NCT06793228 · CT.gov ↗
What to watch
Phase 4Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-01-15 · NCT07320105 · CT.gov ↗
What to watch
Phase 1/2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-01-25 · NCT04699188 · CT.gov ↗
What to watch
Phase 2Small Cell Lung CancerNot yet recruiting
Est. primary completion 2027-01-31 · NCT06851819 · CT.gov ↗
What to watch
Phase 2Refractory Solid Cancer Patients Unexposed to ImmunotherapyNot yet recruiting
Est. primary completion 2027-01-31 · NCT07300891 · CT.gov ↗
What to watch
February 2027 (2)
Phase 2Lung CarcinomaRecruiting
Est. primary completion 2027-02-20 · NCT07019675 · CT.gov ↗
What to watch
Phase 2Gastric CancerRecruiting
Est. primary completion 2027-02-28 · NCT05687357 · CT.gov ↗
What to watch
March 2027 (9)
Phase 1Advanced Pancreatic Ductal AdenocarcinomaNot yet recruiting
Est. primary completion 2027-03 · NCT07348107 · CT.gov ↗
What to watch
Phase 2Small Cell Lung CancerRecruiting
Est. primary completion 2027-03-01 · NCT06838208 · CT.gov ↗
What to watch
Phase 2Intrahepatic Cholangiocellular CarcinomaRecruiting
Est. primary completion 2027-03-15 · NCT06860477 · CT.gov ↗
What to watch
Phase 1Advanced Malignant Skin Neoplasm, Metastatic Malignant Skin NeoplasmActive not recruiting
Est. primary completion 2027-03-31 · NCT04387084 · CT.gov ↗
What to watch
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-03-31 · NCT06427941 · CT.gov ↗
What to watch
Phase 2LA HNSCCRecruiting
Est. primary completion 2027-03-31 · NCT06978829 · CT.gov ↗
What to watch
Phase 2Esophageal Squamous Cell CarcinomaNot yet recruiting
Est. primary completion 2027-03-31 · NCT07531979 · CT.gov ↗
What to watch
Phase 2Hepatocellular Carcinoma (HCC)Recruiting
Est. primary completion 2027-03-31 · NCT07413354 · CT.gov ↗
What to watch
Phase 2Rectal CancerRecruiting
Est. primary completion 2027-03-31 · NCT07104604 · CT.gov ↗
What to watch
April 2027 (2)
Phase 2Small Cell Lung CancerNot yet recruiting
Est. primary completion 2027-04-15 · NCT06375109 · CT.gov ↗
What to watch
Phase 3Bladder CancerNot yet recruiting
Est. primary completion 2027-04-15 · NCT06364904 · CT.gov ↗
What to watch
May 2027 (7)
Phase 1Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-05 · NCT06969612 · CT.gov ↗
What to watch
Phase 2Rectal Cancer, Adenocarcinoma, Neoadjuvant Therapy, Immunotherapy, Probio-M9, Tislelizumab, RandomizedRecruiting
Est. primary completion 2027-05-05 · NCT07458529 · CT.gov ↗
What to watch
Phase 1HPV-positive Oropharyngeal Squamous Cell CarcinomaRecruiting
Est. primary completion 2027-05-10 · NCT07565740 · CT.gov ↗
What to watch
Phase 3Nasopharyngeal CarcinomaRecruiting
Est. primary completion 2027-05-15 · NCT06383780 · CT.gov ↗
What to watch
Phase 1/2Lung CancerRecruiting
Est. primary completion 2027-05-30 · NCT05886439 · CT.gov ↗
What to watch
Phase 2Esophageal Squamous Cell CarcinomaRecruiting
Est. primary completion 2027-05-30 · NCT06354140 · CT.gov ↗
What to watch
Phase 1/2HNSCC, Lysogenic HSV Virus, Neoadjuvant Therapy, Immunotherapy, Targeted TherapyActive not recruiting
Est. primary completion 2027-05-31 · NCT07010120 · CT.gov ↗
What to watch
June 2027 (12)
Phase 1/2Advanced Solid TumorRecruiting
Est. primary completion 2027-06 · NCT05978102 · CT.gov ↗
What to watch
Phase 2Hepatocellular Carcinoma (HCC), Portal Vein Tumor ThrombusRecruiting
Est. primary completion 2027-06 · NCT07483359 · CT.gov ↗
What to watch
Phase 2Carcinoma, Hepatocellular, Liver Cell CarcinomaRecruiting
Est. primary completion 2027-06-01 · NCT05366829 · CT.gov ↗
What to watch
Phase 1/2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-06-30 · NCT05651022 · CT.gov ↗
What to watch
Phase 2Relapsed/Refractory Follicular LymphomaNot yet recruiting
Est. primary completion 2027-06-30 · NCT07031700 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2027-06-30 · NCT06977828 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-06-30 · NCT06877299 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-06-30 · NCT07050056 · CT.gov ↗
What to watch
Phase 2HCC, Liver Cirrhosis, Portal HypertensionNot yet recruiting
Est. primary completion 2027-06-30 · NCT07350070 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2027-06-30 · NCT07845916 · CT.gov ↗
What to watch
Phase 3Gastric CancerNot yet recruiting
Est. primary completion 2027-06-30 · NCT07068516 · CT.gov ↗
What to watch
Phase 3Urothelial CarcinomaActive not recruiting
Est. primary completion 2027-06-30 · NCT03967977 · CT.gov ↗
What to watch
July 2027 (2)
Phase 2Cholangiocarcinoma, Hilar Cholangiocarcinoma, Bile Duct CancerRecruiting
Est. primary completion 2027-07-01 · NCT07030140 · CT.gov ↗
What to watch
Phase 2Prostate Cancer, Stage IV Prostate CancerActive not recruiting
Est. primary completion 2027-07-15 · NCT05189457 · CT.gov ↗
What to watch
August 2027 (7)
Phase 1Esophagogastric Junction Adenocarcinoma, Gastric Adenocarcinoma, Esophageal Adenocarcinoma, Resectable Esophagogastric Adenocarcinoma …Recruiting
Est. primary completion 2027-08 · NCT07059299 · CT.gov ↗
What to watch
Phase 2Triple-negative Breast CancerRecruiting
Est. primary completion 2027-08 · NCT04501523 · CT.gov ↗
What to watch
Phase 2Richter TransformationRecruiting
Est. primary completion 2027-08 · NCT04271956 · CT.gov ↗
What to watch
Phase 2Esophageal Squamous Cell CarcinomaNot yet recruiting
Est. primary completion 2027-08-01 · NCT07046221 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-08-10 · NCT07089199 · CT.gov ↗
What to watch
Phase 2Locally Advanced Rectal CancerRecruiting
Est. primary completion 2027-08-10 · NCT07469306 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-08-30 · NCT07925866 · CT.gov ↗
What to watch
September 2027 (8)
Phase 2Advanced Rectal Cancer, Liver Metastasis, Pulmonary Metastasis, Microsatellite Stable Colorectal CarcinomaNot yet recruiting
Est. primary completion 2027-09-01 · NCT05359393 · CT.gov ↗
What to watch
Phase 2Gastric CancerRecruiting
Est. primary completion 2027-09-01 · NCT06560528 · CT.gov ↗
What to watch
Phase 2Rectal Neoplasms, Rectal Cancer, AdenocarcinomaRecruiting
Est. primary completion 2027-09-11 · NCT07888309 · CT.gov ↗
What to watch
Phase 2Head and Neck Cancer Squamous Cell Carcinoma, Skull Base--Cancer, Neoadjuvant Chemoimmunotherapy, Objective Response RateNot yet recruiting
Est. primary completion 2027-09-20 · NCT07145931 · CT.gov ↗
What to watch
Phase 1Advanced Solid TumorRecruiting
Est. primary completion 2027-09-28 · NCT06233942 · CT.gov ↗
What to watch
Phase 1Esophageal Squamous Cell CarcinomaRecruiting
Est. primary completion 2027-09-30 · NCT07317609 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2027-09-30 · NCT06908733 · CT.gov ↗
What to watch
Phase 3Colonic Neoplasms, Neoadjuvant Therapy, Immune Checkpoint InhibitorsNot yet recruiting
Est. primary completion 2027-09-30 · NCT07132008 · CT.gov ↗
What to watch
October 2027 (2)
Phase 2Head &Amp; Neck Squamous Cell CarcinomaRecruiting
Est. primary completion 2027-10-20 · NCT07147426 · CT.gov ↗
What to watch
Phase 3Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction AdenocarcinomaRecruiting
Est. primary completion 2027-10-30 · NCT07043400 · CT.gov ↗
What to watch
November 2027 (4)
Phase 3Colorectal Cancer, Microsatellite Instability HighRecruiting
Est. primary completion 2027-11-01 · NCT06520683 · CT.gov ↗
What to watch
Early phase / not applicableHepatocellular CarcinomaRecruiting
Est. primary completion 2027-11-01 · NCT07243691 · CT.gov ↗
What to watch
Phase 1Peritoneal Metastasis of Gastric and Colorectal Cancer, LDRTNot yet recruiting
Est. primary completion 2027-11-30 · NCT07453875 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2027-11-30 · NCT07231575 · CT.gov ↗
What to watch
December 2027 (31)
Phase 1Advanced Solid TumorRecruiting
Est. primary completion 2027-12 · NCT05547321 · CT.gov ↗
What to watch
Phase 1mCRPCNot yet recruiting
Est. primary completion 2027-12 · NCT07389187 · CT.gov ↗
What to watch
Phase 1/2Rectal CancerRecruiting
Est. primary completion 2027-12 · NCT07561060 · CT.gov ↗
What to watch
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-12 · NCT05431270 · CT.gov ↗
What to watch
Phase 1/2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2027-12 · NCT07846358 · CT.gov ↗
What to watch
Phase 2Pancreatic CancerRecruiting
Est. primary completion 2027-12 · NCT05604560 · CT.gov ↗
What to watch
Phase 2Muscle Invasive Bladder Cancer (MIBC)Recruiting
Est. primary completion 2027-12 · NCT07296705 · CT.gov ↗
What to watch
Phase 2Esophageal Squamous Cell CarcinomaRecruiting
Est. primary completion 2027-12 · NCT06764355 · CT.gov ↗
What to watch
Phase 2Biliary Tract CarcinomaRecruiting
Est. primary completion 2027-12 · NCT07099547 · CT.gov ↗
What to watch
Phase 3Rectal CancerRecruiting
Est. primary completion 2027-12 · NCT07132463 · CT.gov ↗
What to watch
Phase 2Minimal Residual Disease, Adjuvant Chemotherapy, Colorectal Cancer, Fruquintinib, Tislelizumab, ctDNAActive not recruiting
Est. primary completion 2027-12-01 · NCT07136077 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-12-10 · NCT07085182 · CT.gov ↗
What to watch
Phase 2Advanced Solid TumorRecruiting
Est. primary completion 2027-12-15 · NCT07669415 · CT.gov ↗
What to watch
Phase 1/2Extranodal NK/T-cell Lymphoma, NK/T-cell Lymphoma, Relapsed or Refractory NK/T-Cell LymphomaRecruiting
Est. primary completion 2027-12-30 · NCT07502768 · CT.gov ↗
What to watch
Phase 3Oral Squamous Cell Carcinoma, Locally Advanced Head and Neck CarcinomaRecruiting
Est. primary completion 2027-12-30 · NCT06258811 · CT.gov ↗
What to watch
Early phase / not applicableInitially Unresectable Hepatocellular CarcinomaNot yet recruiting
Est. primary completion 2027-12-30 · NCT07480382 · CT.gov ↗
What to watch
Phase 1Hepatocellular Carcinoma (HCC)Not yet recruiting
Est. primary completion 2027-12-31 · NCT07077369 · CT.gov ↗
What to watch
Phase 2Rare TumourNot yet recruiting
Est. primary completion 2027-12-31 · NCT06692491 · CT.gov ↗
What to watch
Phase 2Gastric CancerNot yet recruiting
Est. primary completion 2027-12-31 · NCT06764251 · CT.gov ↗
What to watch
Phase 2Nasopharyngeal CarcinomaNot yet recruiting
Est. primary completion 2027-12-31 · NCT06781112 · CT.gov ↗
What to watch
Phase 2Soft Tissue Sarcomas, Angiosarcoma, Fibrosarcoma, Leiomyosarcoma, Pleomorphic Liposarcoma, Malignant Peripheral Nerve Sheath Tumor (MPNST) …Recruiting
Est. primary completion 2027-12-31 · NCT06849986 · CT.gov ↗
What to watch
Phase 2Squamous Cell Carcinoma of External Auditory Canal, Locally Advanced TumorRecruiting
Est. primary completion 2027-12-31 · NCT07370337 · CT.gov ↗
What to watch
Phase 2Relapsed/Refractory Follicular LymphomaRecruiting
Est. primary completion 2027-12-31 · NCT07418190 · CT.gov ↗
What to watch
Phase 2Small Cell Lung CancerRecruiting
Est. primary completion 2027-12-31 · NCT07425795 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-12-31 · NCT07528274 · CT.gov ↗
What to watch
Phase 2Upper Tract Urothelial CarcinomaNot yet recruiting
Est. primary completion 2027-12-31 · NCT07584733 · CT.gov ↗
What to watch
Phase 2Esophageal Squamous Cell CarcinomaNot yet recruiting
Est. primary completion 2027-12-31 · NCT07721103 · CT.gov ↗
What to watch
Phase 2Head and Neck Squamous Cell Carcinoma (HNSCC), HNSCCActive not recruiting
Est. primary completion 2027-12-31 · NCT06673693 · CT.gov ↗
What to watch
Phase 2Esophageal Squamous Cell CarcinomaRecruiting
Est. primary completion 2027-12-31 · NCT07811752 · CT.gov ↗
What to watch
Phase 2Nasopharyngeal CarcinomaRecruiting
Est. primary completion 2027-12-31 · NCT07331428 · CT.gov ↗
What to watch
Early phase / not applicableAdvanced Thyroid Carcinoma, Radioiodine-refractory Differentiated Thyroid Cancer, Poorly Differentiated Thyroid CarcinomaRecruiting
Est. primary completion 2027-12-31 · NCT07068542 · CT.gov ↗
What to watch
2028 (59)
January 2028 (3)
Phase 1Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Head and Neck Carcinoma, Head and Neck Cancer Stage IV …Recruiting
Est. primary completion 2028-01-01 · NCT05526924 · CT.gov ↗
What to watch
Phase 2Esophageal Squamous Cell CarcinomaNot yet recruiting
Est. primary completion 2028-01-31 · NCT07678580 · CT.gov ↗
What to watch
Phase 2Hepatocellular Carcinoma (HCC)Recruiting
Est. primary completion 2028-01-31 · NCT07463248 · CT.gov ↗
What to watch
February 2028 (2)
Phase 2Nasopharyngeal CarcinomaNot yet recruiting
Est. primary completion 2028-02 · NCT07388758 · CT.gov ↗
What to watch
Phase 2Esophageal Squamous Cell CarcinomaRecruiting
Est. primary completion 2028-02-28 · NCT07733180 · CT.gov ↗
What to watch
March 2028 (7)
Phase 1Advanced or Recurrent Solid TumorsRecruiting
Est. primary completion 2028-03 · NCT06541639 · CT.gov ↗
What to watch
Phase 2Colorectal CancerRecruiting
Est. primary completion 2028-03 · NCT06722183 · CT.gov ↗
What to watch
Phase 2HCC - Hepatocellular CarcinomaNot yet recruiting
Est. primary completion 2028-03 · NCT07363512 · CT.gov ↗
What to watch
Phase 2Hodgkin LymphomaActive not recruiting
Est. primary completion 2028-03 · NCT05502250 · CT.gov ↗
What to watch
Phase 1/2Gastric CancerNot yet recruiting
Est. primary completion 2028-03-30 · NCT06871527 · CT.gov ↗
What to watch
Phase 1Solid TumorRecruiting
Est. primary completion 2028-03-31 · NCT06349837 · CT.gov ↗
What to watch
Phase 2Small Cell Lung CancerRecruiting
Est. primary completion 2028-03-31 · NCT07109401 · CT.gov ↗
What to watch
April 2028 (6)
Phase 1/2Colorectal Cancer (Diagnosis), Colorectal Cancer Metastatic, Colorectal Cancer (CRC), ImmunotherapyRecruiting
Est. primary completion 2028-04 · NCT07244705 · CT.gov ↗
What to watch
Phase 2Angioimmunoblastic T-Cell Lymphoma Recurrent, Angioimmunoblastic T-Cell Lymphoma RefractoryRecruiting
Est. primary completion 2028-04-01 · NCT07058103 · CT.gov ↗
What to watch
Phase 3Gastric CancerRecruiting
Est. primary completion 2028-04-01 · NCT06793917 · CT.gov ↗
What to watch
Phase 2Gastric or Esophagogastric Junction AdenocarcinomaRecruiting
Est. primary completion 2028-04-30 · NCT07569068 · CT.gov ↗
What to watch
Phase 2Head and Neck Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma (HNSCC), Head & Neck Cancer, Neoadjuvant TherapyRecruiting
Est. primary completion 2028-04-30 · NCT07601737 · CT.gov ↗
What to watch
Phase 3Nasopharyngeal CarcinomaNot yet recruiting
Est. primary completion 2028-04-30 · NCT07373990 · CT.gov ↗
What to watch
May 2028 (1)
Phase 3Gastric CarcinomaNot yet recruiting
Est. primary completion 2028-05-15 · NCT06944496 · CT.gov ↗
What to watch
June 2028 (6)
Phase 1Pancreatic CancerRecruiting
Est. primary completion 2028-06 · NCT07671339 · CT.gov ↗
What to watch
Phase 2Gastric CancerNot yet recruiting
Est. primary completion 2028-06 · NCT07685704 · CT.gov ↗
What to watch
Phase 2Gastroesophageal AdenocarcinomaRecruiting
Est. primary completion 2028-06-01 · NCT07290985 · CT.gov ↗
What to watch
Phase 1Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-06-30 · NCT06868732 · CT.gov ↗
What to watch
Phase 2Hepatocellular Carcinoma (HCC)Recruiting
Est. primary completion 2028-06-30 · NCT07047586 · CT.gov ↗
What to watch
Phase 2Gastroesophageal Junction AdenocarcinomaNot yet recruiting
Est. primary completion 2028-06-30 · NCT07609667 · CT.gov ↗
What to watch
July 2028 (6)
Phase 2Colorectal CancerRecruiting
Est. primary completion 2028-07 · NCT06529523 · CT.gov ↗
What to watch
Phase 2Esophageal Cancer Stage IIINot yet recruiting
Est. primary completion 2028-07-01 · NCT06965829 · CT.gov ↗
What to watch
Phase 2Gastric CancerNot yet recruiting
Est. primary completion 2028-07-01 · NCT07655661 · CT.gov ↗
What to watch
Phase 4Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2028-07-01 · NCT06356675 · CT.gov ↗
What to watch
Phase 1Advanced Solid TumorsRecruiting
Est. primary completion 2028-07-23 · NCT06596473 · CT.gov ↗
What to watch
Phase 2Esophageal Squamous Cell CarcinomaNot yet recruiting
Est. primary completion 2028-07-31 · NCT07686926 · CT.gov ↗
What to watch
August 2028 (2)
Phase 1/2Advanced Solid Tumor Cancer, Triple-Negative Breast Cancer (TNBC), CNS Disease, Breast CancerNot yet recruiting
Est. primary completion 2028-08 · NCT07681297 · CT.gov ↗
What to watch
Phase 2New Diagnosed Angioimmunoblastic T-Cell LymphomaRecruiting
Est. primary completion 2028-08-01 · NCT07168317 · CT.gov ↗
What to watch
September 2028 (4)
Phase 3Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-09 · NCT06745908 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2028-09-08 · NCT06614231 · CT.gov ↗
What to watch
Phase 2Soft Tissue Sarcoma (STS), Utidelone, DoxorubicinNot yet recruiting
Est. primary completion 2028-09-20 · NCT07842276 · CT.gov ↗
What to watch
Phase 1RAS Mutation, Advanced Solid Tumor, Metastatic Solid TumorRecruiting
Est. primary completion 2028-09-30 · NCT07746141 · CT.gov ↗
What to watch
October 2028 (9)
Phase 2Nasopharyngeal CarcinomaRecruiting
Est. primary completion 2028-10 · NCT06093061 · CT.gov ↗
What to watch
Phase 3Head and Neck Squamous Cell CarcinomasRecruiting
Est. primary completion 2028-10 · NCT05582265 · CT.gov ↗
What to watch
Phase 3AdenocarcinomaRecruiting
Est. primary completion 2028-10 · NCT07385703 · CT.gov ↗
What to watch
Phase 1Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2028-10-01 · NCT07842887 · CT.gov ↗
What to watch
Phase 2Hodgkin LymphomaNot yet recruiting
Est. primary completion 2028-10-01 · NCT05627115 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2028-10-30 · NCT07432984 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2028-10-31 · NCT07561983 · CT.gov ↗
What to watch
Phase 2Oral Squamous Cell Carcinoma (OSCC), Oropharyngeal Squamous Cell Carcinoma (OPSCC)Not yet recruiting
Est. primary completion 2028-10-31 · NCT07812467 · CT.gov ↗
What to watch
Phase 2/3Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-10-31 · NCT07131319 · CT.gov ↗
What to watch
November 2028 (2)
Phase 2Hodgkin LymphomaRecruiting
Est. primary completion 2028-11 · NCT05977673 · CT.gov ↗
What to watch
Phase 2CNS LymphomaRecruiting
Est. primary completion 2028-11-30 · NCT06876688 · CT.gov ↗
What to watch
December 2028 (11)
Phase 2Esophageal Squamous Cell CarcinomaNot yet recruiting
Est. primary completion 2028-12 · NCT07128693 · CT.gov ↗
What to watch
Phase 2/3Esophageal Squamous Cell CarcinomaRecruiting
Est. primary completion 2028-12 · NCT07554456 · CT.gov ↗
What to watch
Phase 4Small Cell Lung CancerNot yet recruiting
Est. primary completion 2028-12-10 · NCT07485920 · CT.gov ↗
What to watch
Phase 2HCC - Hepatocellular CarcinomaNot yet recruiting
Est. primary completion 2028-12-30 · NCT07518706 · CT.gov ↗
What to watch
Phase 1Bladder Urothelial Carcinoma, Lymph Node MetastasisEnrolling by invitation
Est. primary completion 2028-12-31 · NCT07353294 · CT.gov ↗
What to watch
Phase 1/2Malignant TumorsNot yet recruiting
Est. primary completion 2028-12-31 · NCT07694765 · CT.gov ↗
What to watch
Phase 2Digestive System NeoplasmsNot yet recruiting
Est. primary completion 2028-12-31 · NCT07196540 · CT.gov ↗
What to watch
Phase 2Esophageal Squamous Cell CarcinomaRecruiting
Est. primary completion 2028-12-31 · NCT07039162 · CT.gov ↗
What to watch
Phase 2Small Cell Lung CancerRecruiting
Est. primary completion 2028-12-31 · NCT07815223 · CT.gov ↗
What to watch
Phase 2Esophageal Squamous Cell CarcinomaRecruiting
Est. primary completion 2028-12-31 · NCT07700667 · CT.gov ↗
What to watch
Phase 4Liver CancerNot yet recruiting
Est. primary completion 2028-12-31 · NCT07790419 · CT.gov ↗
What to watch
2029 (27)
January 2029 (1)
Phase 2Hepato Cellular Carcinoma (HCC)Recruiting
Est. primary completion 2029-01-15 · NCT07328009 · CT.gov ↗
What to watch
February 2029 (2)
Phase 2Gastric or Gastroesophageal Junction AdenocarcinomaRecruiting
Est. primary completion 2029-02-20 · NCT07408609 · CT.gov ↗
What to watch
Phase 1Advanced Solid Tumor, Solid TumorRecruiting
Est. primary completion 2029-02-28 · NCT05981703 · CT.gov ↗
What to watch
March 2029 (2)
Phase 1Pancreatic Adenocarcinoma MetastaticRecruiting
Est. primary completion 2029-03 · NCT07377045 · CT.gov ↗
What to watch
Phase 2Head and Neck Squamous Cell CarcinomaRecruiting
Est. primary completion 2029-03-25 · NCT06323369 · CT.gov ↗
What to watch
April 2029 (3)
Phase 2Large B-cell LymphomaRecruiting
Est. primary completion 2029-04 · NCT06167785 · CT.gov ↗
What to watch
Phase 3Cancer, Lung Cancer, Colo-rectal Cancer, Pancreas Cancer, Soft Tissue SarcomaRecruiting
Est. primary completion 2029-04 · NCT06332274 · CT.gov ↗
What to watch
Phase 1Advanced Solid TumorRecruiting
Est. primary completion 2029-04-30 · NCT07414836 · CT.gov ↗
What to watch
May 2029 (2)
Phase 3Laryngeal Carcinoma, Hypopharyngeal CarcinomaNot yet recruiting
Est. primary completion 2029-05-01 · NCT06957938 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2029-05-31 · NCT07609121 · CT.gov ↗
What to watch
June 2029 (5)
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2029-06 · NCT07729670 · CT.gov ↗
What to watch
Phase 4Non-Small Cell Lung CancerRecruiting
Est. primary completion 2029-06 · NCT07744698 · CT.gov ↗
What to watch
Phase 1/2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2029-06-11 · NCT07468071 · CT.gov ↗
What to watch
Phase 3Gastric CarcinomaRecruiting
Est. primary completion 2029-06-30 · NCT07315750 · CT.gov ↗
What to watch
Early phase / not applicableNasopharyngeal CarcinomaActive not recruiting
Est. primary completion 2029-06-30 · NCT07248696 · CT.gov ↗
What to watch
July 2029 (2)
Phase 2Hepatocellular Carcinoma (HCC)Not yet recruiting
Est. primary completion 2029-07 · NCT07729592 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2029-07-19 · NCT07086456 · CT.gov ↗
What to watch
August 2029 (2)
Phase 2Locally Advanced Rectal Cancer (LARC)Recruiting
Est. primary completion 2029-08 · NCT06940388 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2029-08-15 · NCT07120282 · CT.gov ↗
What to watch
September 2029 (1)
Phase 3Gastroesophageal AdenocarcinomaNot yet recruiting
Est. primary completion 2029-09 · NCT07763171 · CT.gov ↗
What to watch
October 2029 (1)
Phase 2Esophageal Squamous Cell CarcinomaRecruiting
Est. primary completion 2029-10 · NCT07205731 · CT.gov ↗
What to watch
November 2029 (1)
Phase 2/3Classical Hodgkin Lymphoma, Child, Adolescent, Young Adult, Metabolic Response, Survival, Treatment, Brentuximab Vedotin, PET ScanRecruiting
Est. primary completion 2029-11-15 · NCT06563245 · CT.gov ↗
What to watch
December 2029 (5)
Phase 2HPV-unrelated Head and Neck Squamous Cell CarcinomaNot yet recruiting
Est. primary completion 2029-12 · NCT07776340 · CT.gov ↗
What to watch
Phase 2HCC - Hepatocellular Carcinoma, DiabetesRecruiting
Est. primary completion 2029-12 · NCT07557914 · CT.gov ↗
What to watch
Phase 3Small Cell Lung CancerRecruiting
Est. primary completion 2029-12 · NCT07502300 · CT.gov ↗
What to watch
Phase 1Pseudomyxoma PeritoneiRecruiting
Est. primary completion 2029-12-31 · NCT07341360 · CT.gov ↗
What to watch
Phase 2Metastatic Colorectal CancerRecruiting
Est. primary completion 2029-12-31 · NCT06856837 · CT.gov ↗
What to watch
2030 (6)
January 2030 (2)
Phase 3Intrahepatic Cholangiocarcinoma (Icc)Not yet recruiting
Est. primary completion 2030-01 · NCT07691515 · CT.gov ↗
What to watch
Phase 3HCC - Hepatocellular CarcinomaRecruiting
Est. primary completion 2030-01-31 · NCT07475026 · CT.gov ↗
What to watch
June 2030 (1)
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2030-06-30 · NCT07775040 · CT.gov ↗
What to watch
July 2030 (1)
Phase 2Cholangiocarcinoma, Biliary Tract Cancer (BTC)Not yet recruiting
Est. primary completion 2030-07-01 · NCT06903273 · CT.gov ↗
What to watch
October 2030 (1)
Phase 1/2Advanced Solid Tumor CancerEnrolling by invitation
Est. primary completion 2030-10-19 · NCT07847905 · CT.gov ↗
What to watch
December 2030 (1)
Phase 2TNBC, Triple Negative Breast CancerNot yet recruiting
Est. primary completion 2030-12-14 · NCT07271992 · CT.gov ↗
What to watch
2031 (5)
June 2031 (1)
Phase 3Esophageal Squamous Cell CarcinomaNot yet recruiting
Est. primary completion 2031-06-28 · NCT06914011 · CT.gov ↗
What to watch
August 2031 (1)
Phase 2Malignant Neoplasms of Digestive OrgansRecruiting
Est. primary completion 2031-08-06 · NCT05934331 · CT.gov ↗
What to watch
October 2031 (1)
Phase 3Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2031-10-30 · NCT07715396 · CT.gov ↗
What to watch
December 2031 (2)
Phase 3Rectal CancerNot yet recruiting
Est. primary completion 2031-12 · NCT07900061 · CT.gov ↗
What to watch
Phase 2Esophageal Squamous Cell CarcinomaRecruiting
Est. primary completion 2031-12-31 · NCT07554521 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

25 August 2026ApprovalFDA approved the TEVIMBRA sBLA for first-line HER2+ gastroesophageal adenocarcinoma (with ZIIHERA and chemotherapy)
US, FDA · Source ↗